<SEC-DOCUMENT>0001193125-26-127609.txt : 20260327
<SEC-HEADER>0001193125-26-127609.hdr.sgml : 20260327
<ACCEPTANCE-DATETIME>20260327080302
ACCESSION NUMBER:		0001193125-26-127609
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260326
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260327
DATE AS OF CHANGE:		20260327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811591163
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39979
		FILM NUMBER:		26801143

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		SUITE 1350
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		SUITE 1350
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vor-20260326.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-27T07:19:04.7058+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:vor="http://vorbiopharma.com/20260326" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_3ad6a7bb-0a3c-4e82-b7b2-2ed287acc6b0" name="dei:AmendmentFlag" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887">false</ix:nonNumeric><ix:nonNumeric id="F_515be33a-e2b8-4032-88e0-b1ff4c15feeb" name="dei:EntityCentralIndexKey" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887">0001817229</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vor-20260326.xsd"/></ix:references><ix:resources><xbrli:context id="C_f6237d00-fd03-4797-806a-1daf158ca887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001817229</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-26</xbrli:startDate><xbrli:endDate>2026-03-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_935fe464-e413-44d6-b3f4-50d209de3de9" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_eb1bec00-4e21-4852-8651-b72a5d00609a" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 26, 2026</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dfa82275-f9bc-472a-bcfe-ab77f3179b3d" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VOR BIOPHARMA INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a88734ca-b46b-408f-bc7e-290760dee1a7" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_735532d5-7eeb-4c3e-8e00-a729b39787e5" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-39979</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a8ed75b6-86ed-4088-852b-f2fbe70fe347" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81-1591163</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_36f5196c-b933-4cd7-bc2f-26dab9df9379" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">500 Boylston Street, Suite 1350</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f5446245-d240-4e80-a7ea-4e0d17a0d440" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_f8abad7e-6c07-451d-add9-762ac45ae212" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_caaf3df7-6311-4175-a800-dc8c7d7ebb3d" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">02116</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_0bf4d266-efb6-4d35-b707-c544d2c1fa2d" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_8681e0ac-196b-4655-b225-4bb20598b485" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">655-6580</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5131cabe-ec52-4066-b8db-1ff659abe7a8" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_821435f4-76d8-451e-9d41-4d54b35ec60d" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec4dd139-6f68-4422-895b-75a209bfeeeb" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87592c07-b026-41c0-8da3-1955e9323a53" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5c910ee7-6a13-4141-bd97-2a2b01a436f3" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3a3d56a9-25d7-4ec3-bff5-39c79ae2bb85" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VOR</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e4221552-11c1-4f6e-b14e-a2d9af0c210c" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_6af7632f-3eb6-4321-8eda-ddf5b2affaeb" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_5894deae-bbf3-4dc4-bcd9-d6be9af5d0f4" contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1.01 Entry into a Material Definitive Agreement.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 26, 2026, Vor Biopharma Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with entities affiliated with TCGX (the &#8220;Investors&#8221;) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the &#8220;Private Placement&#8221;). The Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Investors, on the other hand, and customary conditions to closing. The closing of the Private Placement is expected to occur on March 30, 2026, subject to customary closing conditions. Upon the closing of the Private Placement, the Company will have 54,185,582 shares of common stock outstanding. The Company intends to use the net proceeds from the Private Placement to advance development of its clinical pipeline and for general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated March 26, 2026 (the &#8220;Registration Rights Agreement&#8221;), with the Investors. Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the Securities and Exchange Commission (&#8220;SEC&#8221;) a registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) to register for resale the Shares within 30 days of the closing date of the Private Placement and to use its reasonable best efforts to have the Registration Statement declared effective as soon as possible, but no later than 60 days after the closing date of the Private Placement, subject to extension under the terms of the Registration Rights Agreement. The Registration Rights Agreement provides for liquidated damages payable to the Investors if the Company fails to meet certain filing or effectiveness deadlines, subject to specified caps. The Registration Rights Agreement includes customary provisions regarding payment of fees and expenses and indemnification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Purchase Agreement and the form of Registration Rights Agreement, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The representations, warranties and covenants contained in the Purchase Agreement and the Registration Rights Agreement were made solely for the benefit of the parties to the Purchase Agreement and the Registration Rights Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase Agreement and the Registration Rights Agreement are incorporated herein by reference only to provide investors with information regarding the terms of the Purchase Agreement and the Registration Rights Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3.02 Unregistered Sales of Equity Securities.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The disclosures set forth in Item 1.01 above regarding the Private Placement are incorporated into this Item 3.02.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Shares have not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each Investor has represented that it is a &#8220;qualified institutional buyer,&#8221; as defined in Rule 144A under the Securities Act or an institutional &#8220;accredited investor&#8221; (as defined in Rule 501(a) under the Securities Act), that it is purchasing the Shares solely for such Investor&#8217;s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the Shares in violation of the Securities Act. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 27, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:21.1%;box-sizing:content-box;"/>
     <td style="width:78.9%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vor-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement.</span></a></p></td>
    </tr>
    <tr style="height:12.6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vor-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement.</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vor-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated March 27, 2026.</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;enable,&#8221; &#8220;expect,&#8221; &#8220;initiate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Current Report on Form 8-K include the Company&#8217;s expectations regarding the closing of the Private Placement and the use of proceeds therefrom, the anticipated filing of a registration statement to cover resales of the Shares, and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of clinical trials and clinical development of the Company&#8217;s product candidates; availability and timing of results from clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to conduct trials or to market products; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption &#8220;Risk Factors&#8221; included in the Company&#8217;s most recent annual or quarterly report and in other reports it has filed or may file with the SEC. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vor Biopharma Inc.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 27, 2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jean-Paul Kress</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jean-Paul Kress<br/>Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>vor-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-27T07:19:05.0334+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES PURCHASE AGREEMENT</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES PURCHASE AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is dated as of March 26, 2026, by and among Vor Biopharma Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and each of the purchasers listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached to this Agreement (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon the terms and subject to the conditions stated in this Agreement, shares of Common Stock (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, contemporaneously with the sale of the Shares, the parties hereto will execute and deliver a Registration Rights Agreement, substantially in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, pursuant to which the Company will agree to provide certain registration rights in respect of the Shares under the Securities Act and applicable state securities laws.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company and each Investor, severally and not jointly, agree as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As used in this Agreement, the following terms shall have the following respective meanings:</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediates, controls, is controlled by or is under common control with such Person.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the recitals.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Bylaws of the Company, as currently in effect.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Certificate of Incorporation of the Company, as currently in effect.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefit Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefit Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means employee benefit plans as defined in Section 3(3) of ERISA and all other employee benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by the Company or to which the Company or any of its subsidiaries is obligated to contribute for employees or former employees of the Company and its subsidiaries.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the board of directors of the Company.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.03pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Company&#x2019;s common stock, par value $0.0001 per share.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the recitals.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.30</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Document</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug Regulatory Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food and Drug Administration (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or other foreign, state, local or comparable governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or biological products and drug or biological product candidates.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.15</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Employee Retirement Income Security Act of 1974, as amended.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated thereunder.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.8(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fundamental Representations&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means the representations and warranties made by the Company in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 3.1 (Organization and Power)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2 (Capitalization)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.4 (Authorization)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.5 (Valid Issuance)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.6 (No Conflict)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.7 (Consents)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.8 (SEC Filings; Financial Statements)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.18 (Nasdaq Stock Market)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.19 (Sarbanes-Oxley Act)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.23 (Price Stabilization of Common Stock)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.24 (Investment Company Act)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.25 (General Solicitation; No Integration or Aggregation)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.26 (Brokers and Finders)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.27 (Reliance by the Investors)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.28 (No Additional Agreements)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.8(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.31</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Person&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; have the meanings set forth in the recitals.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IT Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.30</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lock-up Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, (a) was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities, stockholders&#x2019; equity or results of operations of the Company and its subsidiaries, taken as a whole, or (b) materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under this Agreement, the other Transaction Agreements, or with respect to the Closing, or would reasonably be expected to do so.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market LLC.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">National Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question, together with any successor thereto: the NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market and the Nasdaq Capital Market.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.30</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.31</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.31</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Processing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.31</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;SEC Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) the Company&#x2019;s most recently filed Annual Report on Form 10-K and (b) all Quarterly Reports on Form 10-Q or Current Reports on Form 8-K filed or furnished (as applicable) by the Company following the end of the most recent fiscal year for which an Annual Report on Form 10-K has been filed and prior to the execution of this Agreement, together in each case with any documents incorporated by reference therein or exhibits thereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Securities Act of 1933, as amended, and all of the rules and regulations promulgated thereunder.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth in the recitals.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; include, without limitation, (a) all &#x201c;short sales&#x201d; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, &#x201c;put equivalent positions&#x201d; (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and (b) sales and other transactions through non-U.S. broker dealers or non-U.S. regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto), whether or not imposed on the Company or its subsidiaries, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding, employment, social security, workers&#x2019; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and customs duties.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Returns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means returns, reports, information statements and other documentation (including any additional or supporting material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any amended returns required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means this Agreement and the Registration Rights Agreement.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Common Stock, Computershare Trust Company, N.A., or such other financial institution that provides transfer agent services as the Company may engage from time to time.</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase and Sale of Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase and Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Investors, severally and not jointly, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agree to purchase, the number of Shares, for the aggregate purchase price, set forth opposite the Investor&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The price per Share is $14.05.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   Subject to the satisfaction or waiver of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement, the closing of the purchase and sale of the Shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and the date on which the Closing occurs, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall occur remotely via the exchange of documents and signatures at such time as agreed to by the Company and the Investors but (i) in no event earlier than the second Business Day after the date of this Agreement and (ii) in no event later than the fifth Business Day after the date of this Agreement.  At the Closing, the Shares shall be issued and registered in the name of the Investor, or in such nominee name(s) as designated by such Investor, representing the number of Shares to be purchased by the Investor at the Closing as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case against payment to the Company of the purchase price therefor (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate Purchase Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in full, by wire transfer to the Company of immediately available funds, at or prior to the Closing, in accordance with wire instructions provided by the Company to the Investors at least one Business Day prior to the Closing. On the Closing Date, the Company will cause the Transfer Agent to issue the Shares in book-entry form, free and clear of all restrictive and other legends (except as expressly provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.10 hereof</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and the Company shall provide evidence of such issuance from the Company&#x2019;s Transfer Agent as soon as reasonably practicable following the Closing Date to each Investor. In the event that the Closing has not occurred within one Business Day after the expected Closing Date, unless otherwise agreed by the Company and such Investor, the Company shall promptly (but no later than one Business Day thereafter) return the previously wired Aggregate Purchase Amount to each respective Investor by wire transfer of United States dollars in immediately available funds to the account specified by each Investor, and any book entries for the Shares shall be deemed cancelled; provided that, unless this Agreement has been terminated pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such return of funds shall not terminate this Agreement or relieve such Investor of its obligation to purchase, or the Company of its obligation to issue and sell, the Shares at the Closing.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth in the SEC Reports (other than as to the Fundamental Representations, which are not so qualified), the Company hereby represents and warrants to each of the Investors that the statements contained in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are true and correct as of the date of this Agreement and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization and Power</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described in the SEC Reports and is qualified to do business in each jurisdiction in which the character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not reasonably be expected to have a Material Adverse Effect.  Each of the Company&#x2019;s subsidiaries is (i) duly incorporated and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite power and authority to carry on its business as now conducted and to own or lease its properties and (ii) qualified to do business as a foreign corporation and in good standing in each jurisdiction in which such qualification is </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">required, except in each case as would not reasonably be expected to have a Material Adverse Effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company&#x2019;s disclosure of its authorized, issued and outstanding capital stock in the SEC Reports containing such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and such shares were issued in compliance in all material respects with applicable state and federal securities laws and any rights of third parties.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth in the Transaction Agreements or as disclosed in the SEC Reports, the Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company&#x2019;s presently outstanding securities or any of its securities that may hereafter be issued, other than such rights and obligations that have expired or been satisfied or waived.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Shares. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of the Shares, the authorization, execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated herein, including the issuance and sale of the Shares, has been taken, including, without limitation, the approval of the Board of Directors (or a committee thereof) in accordance with Section 144(a)(1) of the Delaware General Corporation Law (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DGCL</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by each Investor of this Agreement and that this Agreement constitutes the legal, valid and binding agreement of each Investor, this Agreement constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). Upon its execution by the Company and the other parties thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement will constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valid Issuance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Shares being purchased by the Investors hereunder have been duly and validly authorized and, upon issuance pursuant to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement, will be duly and validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under applicable state and federal securities laws), and the holder of the Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties made by the Investors in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the offer and sale of the Shares to the Investors is and will be (i) exempt from the registration and prospectus delivery requirements of the Securities Act and (ii) exempt from (or otherwise not subject to) the registration and qualification requirements of applicable securities laws of the states of the United States.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflict</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The execution, delivery and performance of the Transaction Agreements by the Company, the issuance and sale of the Shares and the consummation of the other transactions contemplated by the Transaction Agreements will not (i) violate any provision of the Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws of the Company, (ii) conflict with or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to the Company or any of its subsidiaries or their respective properties or assets, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any of its subsidiaries is subject (including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, or by which any property or asset of the Company or any of its subsidiaries is bound or affected, except, in the case of clauses (ii) and (iii), as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Assuming the accuracy of the representations and warranties of the Investors, no consent, approval, authorization, filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization, execution or delivery by the Company of the Transaction Agreements, the issuance and sale of the Shares and the performance by the Company of its other obligations under the Transaction Agreements, except (a) as have been or will be obtained or made under the Securities Act or the Exchange Act, (b) the filing of any requisite notices and/or application(s) to the National Exchange for the issuance and sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (c) customary post-closing filings with the SEC or pursuant to state securities laws in connection with the offer and sale of the Shares by the Company in the manner contemplated herein, which will be filed on a timely basis, (d) the filing of the registration statement required to be filed by the Registration Rights Agreement, or (e) such that the failure of which to obtain would not have a Material Adverse Effect. All notices, consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall remain in full force and effect, on or prior to the Closing.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC Filings; Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has filed all forms, statements, certifications, reports and documents required to be filed by it with the SEC under Section 13, 14(a) and 15(d) of the Exchange Act for the one year preceding the date of this Agreement and is in compliance with </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Instruction I.A.3 of Form S-3.  As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of the Exchange Act, and, as of the time they were filed, none of the filed SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the SEC Reports. To the Company&#x2019;s knowledge, none of the SEC Reports are the subject of an ongoing SEC review. The interactive data in eXtensible Business Reporting Language included in the SEC Reports fairly presents the information called for in all material respects and has been prepared in accordance with the SEC&#x2019;s rules and guidelines applicable thereto. The Company is not, and has never been, an issuer subject to Rule 144(i) under the Securities Act.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of the Company included in the SEC Reports (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and fairly present in all material respects the consolidated financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods therein specified, all in accordance with United States generally accepted accounting principles (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (except as otherwise noted therein, and in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain certain footnotes and are subject to normal and recurring year-end adjustments) applied on a consistent basis throughout the periods therein specified (unless otherwise noted therein). Except as set forth in the Financial Statements filed prior to the date of this Agreement, the Company has not incurred any liabilities, contingent or otherwise, except (i) those incurred in the ordinary course of business, consistent with past practices since the date of such financial statements or (ii) liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Absence of Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Between December 31, 2025 and the date of this Agreement, (a) the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto); (b) no material change to any material contract or arrangement by which the Company or any of its subsidiaries is bound or to which any of its assets or properties is subject has been entered into that has not been disclosed in the SEC Reports; and (c) there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect; provided, however, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the Company is not disproportionately affected thereby;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	any change that generally affects industries in which the Company and its subsidiaries conduct business, provided that the Company is not disproportionately affected thereby;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, epidemic or similar health emergency, and other force majeure events in the United States or any other location, provided that the Company is not disproportionately affected thereby;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	national or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)	material changes in laws after the date of this Agreement; and</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii)	in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses, earnings or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v) of this definition).</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Absence of Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or, to the Company&#x2019;s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that have had or would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been, the subject of any action involving a claim of violation of or liability under federal or state securities laws relating to the Company or such subsidiary or a claim of breach of fiduciary duty relating to the Company or such subsidiary.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Law; Permits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect.  The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company and its subsidiaries as currently conducted, except where the failure to possess currently such Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect.  Neither the Company nor any subsidiary has received any written (or, to the Company&#x2019;s knowledge, oral) notice regarding any revocation or material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company owns or has valid and enforceable licenses or other rights to all patents, copyrights, copyrightable works, trademarks, service marks, trade names, and service names (including all applications and registrations relating to any of the foregoing), and all inventions, know-how, trade secrets and other proprietary or confidential information (whether or not patentable), systems or procedures and all other technology and intellectual property rights necessary for the conduct, or the proposed conduct, of the business of the Company in the manner described in the SEC Reports (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); the Company Intellectual Property disclosed in the SEC Reports as being owned by the Company is owned by the Company free and clear of all material liens, security interests, and encumbrances, and to the Company&#x2019;s knowledge, there are no rights of third parties to such Company Intellectual Property; to the Company&#x2019;s knowledge, the Company Intellectual Property is valid, enforceable and subsisting; and other than as disclosed in the SEC Reports, (i) the Company is not obligated to pay a material royalty, grant a material license, or provide other material consideration to any third party in connection with the Company Intellectual Property, (ii) no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, alleging that the conduct of the business of the Company in the manner described in the SEC Reports is infringing, misappropriating, diluting or otherwise violating any intellectual property rights of others, (iii) no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging the validity, enforceability, scope, registration, ownership or use of any of the Company Intellectual Property, (iv) no action, suit, claim or other proceeding is pending or, to the knowledge of the Company, is threatened, challenging the Company&#x2019;s rights in or to any Company Intellectual Property, (v) to the Company&#x2019;s knowledge, no third party has any ownership right in or to any Company Intellectual Property in any field of use that is exclusively licensed to the Company, other than any licensor to the Company of such Company Intellectual Property, (vi) no employee, consultant or independent contractor of the Company is, to the Company&#x2019;s knowledge, in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer or independent contractor where the basis of such violation relates to such employee&#x2019;s employment or independent contractor&#x2019;s engagement with the Company or actions undertaken while employed or engaged with the Company, (vii) the Company has taken reasonable measures to protect its material confidential information and material trade secrets and to maintain and safeguard the material Company Intellectual Property, including the execution of appropriate nondisclosure and confidentiality agreements, and (viii) the Company has complied with the material terms of each agreement pursuant to which the Company Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect; except in each of (i)&#x2013;(viii) such as would not, if determined adversely to the Company, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. All patents and patent applications within the Company Intellectual Property disclosed in the SEC </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reports as being owned by the Company have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, there are no material defects in any of such patents or patent applications; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the United States Patent and Trademark Office (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">USPTO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications; except such as would not, if determined adversely to the Company, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.13</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection and Affordable Care Act of 2010, as amended, and other applicable laws, rules and regulations.  The Company and its subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding employment, except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect.  There is no labor dispute, strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may interfere with the business activities of the Company, except where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.14</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All Tax Returns of the Company and its subsidiaries required by law to be filed have been filed and all Taxes shown as due on such returns or that otherwise have been assessed, which are due and payable, have been paid, except: (i) assessments against which appeals have been or will be promptly taken in good faith and as to which adequate reserves have been provided in accordance with the applicable accounting principles, or (ii) as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its subsidiaries are presently in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn.  There are no liens on any of the assets of the Company.  At all times since inception, the Company has been and continues to be classified as a corporation for U.S. federal income tax purposes.  Neither the Company nor any of its subsidiaries has been a United States real property holding corporation within the meaning of Code Section 897(c)(2) during the period specified in Code Section 897(c)(1)(A)(ii).  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.15</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) have received all permits and other Governmental Authorizations required under applicable Environmental Laws to conduct their business and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reasonably be expected to have a Material Adverse Effect.  None of the Company nor any of its subsidiaries has received since January 1, 2026, any written notice or other communication (in writing or otherwise), whether from a governmental authority or other Person, that alleges that the Company or any subsidiary is not in compliance with any Environmental Law and, to the knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#x2019;s or any subsidiary&#x2019;s compliance in any material respects with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material Adverse Effect.  To the knowledge of the Company: (i) no current or (during the time a prior property was leased or controlled by the Company) prior property leased or controlled by the Company or any subsidiary has received since January 1, 2026, any written notice or other communication relating to property owned or leased at any time by the Company, whether from a governmental authority, or other Person, that alleges that such current or prior owner or the Company or any subsidiary is not in compliance with or violated any Environmental Law relating to such property and (ii) the Company has no material liability under any Environmental Law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.16</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each of the Company and its subsidiaries has good and marketable title to all personal property owned by it that is material to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its subsidiaries, as the case may be.  Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or its subsidiaries, as the case may be.  The Company does not own any real property.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.17</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased) and tangible assets, and each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms of such insurance policies.  Other than customary end-of-policy notifications from insurance carriers, since January 1, 2026, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any material insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.18</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nasdaq Stock Market</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Global Select Market under the symbol &#x201c;VOR&#x201d;. The Company is in compliance with all listing requirements of Nasdaq applicable to the Company. As of the date of this Agreement, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the Nasdaq Global Select Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date of this Agreement that is designed to terminate the registration of the Common Stock under the Exchange Act.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.19</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company is, and since January 1, 2026, has been, in compliance in all material respects with all applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.20</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Data and Regulatory Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The clinical trials that are described in the SEC Reports were, to the Company&#x2019;s knowledge, and, if still pending, are being, conducted in all material respects in accordance with the protocols submitted to the FDA or any foreign governmental body exercising comparable authority, and all applicable laws and regulations; the descriptions of the clinical trials conducted by or, to the Company&#x2019;s knowledge, on behalf of the Company or by a licensor, and the results thereof, contained in SEC Reports are accurate and complete in all material respects; the Company is not aware of any other pre-clinical studies or clinical trials, the results of which materially call into question the results described in SEC Reports; and the Company has not received any written notices or correspondence from the FDA, any foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or ethics committee or similar body requiring the termination, suspension, material adverse modification or clinical hold of any clinical trials conducted by or on behalf of the Company or by a licensor. Neither the Company or its subsidiaries nor any of their respective officers, employees or directors, nor, to the Company&#x2019;s knowledge, any of its respective agents or clinical investigators, or licensors, has, for the past three (3) years, been excluded, suspended or debarred from participation in any U.S. federal or foreign health care program or human clinical research, or is subject to a governmental inquiry, investigation, proceeding or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion, or convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or comparable foreign law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.21</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Health Care Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company, its subsidiaries and their respective directors, officers and employees, are and for the past three (3) years have been, in compliance with applicable Health Care Laws (defined herein), including, but not limited to, the rules and regulations of the FDA, the U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare &amp; Medicaid Services, the Office for Civil Rights, and the Department of Justice, except for such noncompliance that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health Care Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean, as applicable, the federal Anti-kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Physician Payments Sunshine Act (42 U.S.C. &#167; 1320a-7h), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Act (42 U.S.C. &#167; 1320a-7b(a)), applicable criminal laws relating to health care fraud and abuse, including, without limitation, those set forth at 18 U.S.C. &#167;&#167; 286, 287 and 1349, the exclusion law (42 U.S.C. &#167; 1320a-7), the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167;&#167; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 201 et seq.) and comparable state, local and foreign laws, each as amended from time and the regulations promulgated thereunder. The Company is not a party to or does not have any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred or non-prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority. The Company has not received any written notification, correspondence or any other written or oral communication, including, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without limitation, any Form FDA 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any similar regulatory authority, or any notification of any pending or, to the Company&#x2019;s knowledge, threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action, from any governmental authority alleging or asserting potential or actual material non-compliance by, or material liability of, the Company under any Health Care Laws. Each of the Company and its subsidiaries possesses, and is in compliance with the terms of, all applications, certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations issued by the appropriate governmental authorities and necessary to conduct its business (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including, without limitation, all Licenses required by the Drug Regulatory Agencies. All such Licenses are in full force and effect and the Company is not in violation of any term or conditions of any such License. Each of the Company and its subsidiaries and has fulfilled and performed all of its respective obligations with respect to such Licenses and, no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder of any such License. The Company has not received any written notice of proceedings from the applicable Drug Regulatory Agency proposing to revoke or materially adversely modify any such Licenses and, to the Company&#x2019;s knowledge, no Drug Regulatory Agency has taken any action to limit, suspend or revoke any such License possessed by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.22</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Controls and Disclosure Controls and Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to comply with the requirements of the Exchange Act applicable to the Company and provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that the Company maintains records that in reasonable detail accurately and fairly reflect the Company&#x2019;s transactions and dispositions of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with authorizations of management and the Board of Directors and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&#x2019;s assets that could have a material effect on the Company&#x2019;s financial statements.  Except as disclosed in the Company&#x2019;s SEC Reports filed prior to the date of this Agreement, the Company has not identified any material weaknesses in the design or operation of the Company&#x2019;s internal control over financial reporting.  The Company&#x2019;s &#x201c;disclosure controls and procedures&#x201d; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to provide reasonable assurance that all information (both financial and non-financial) required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to the Company&#x2019;s management as appropriate to allow timely decisions regarding required disclosure.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.23</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Price Stabilization of Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company has not taken, nor will it take, directly or indirectly, any action designed to stabilize or manipulate the price of the Common Stock to facilitate the sale or resale of the Shares.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.24</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Company Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company is not, and immediately after receipt of payment for the Shares will not be, an &#x201c;investment company&#x201d; within the meaning of the U.S. Investment Company Act of 1940, as amended.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.25</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Solicitation; No Integration or Aggregation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither the Company nor any other person or entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect to offers or sales of Shares pursuant to this Agreement.  The Company has not, directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which, to its knowledge, is or will be (i) integrated with the offer and sale of the Shares pursuant to this Agreement for purposes of the Securities Act or (ii) aggregated with prior offerings by the Company for the purposes of the rules and regulations of the Nasdaq Global Select Market. Assuming the accuracy of the representations and warranties of the Investors set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, neither the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.26</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brokers and Finders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither the Company nor any other Person authorized by the Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.27</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance by the Investors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company has a reasonable basis for making each of the representations set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company&#x2019;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.28</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Additional Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   There are no agreements or understandings between the Company and any Investor with respect to the transactions contemplated by the Transaction Agreements other than (i) as specified in the Transaction Agreements and (ii) any side letter agreements with any of the Investors, which side letters the Company has shared with all Investors.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.29</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Bribery and Anti-Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each of the Company, its subsidiaries and, to the knowledge of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope; (B) anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder; or (C) except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to import and export control and economic sanctions, including the U.S. Export Administration Regulations, the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office of Foreign Asset Control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.30</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company and its subsidiaries&#x2019; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IT Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability continuous operation, redundancy and security of all IT Systems. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Data</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the following data used in connection with the Company&#x2019;s and its subsidiaries&#x2019; businesses and in their possession or control: (i) a natural person&#x2019;s name, street address, telephone number, e-mail address, photograph, social security number or other tax identification number, driver&#x2019;s license number, passport number, credit card number or bank information; (ii) information that identifies or may reasonably be used to identify an individual; (iii) any information that would qualify as &#x201c;protected health information&#x201d; under HIPAA; and (iv) any information that would qualify as &#x201c;personal data,&#x201d; &#x201c;personal information&#x201d; (or similar term) under the Privacy Laws. To the Company&#x2019;s knowledge, there have been no breaches, outages or unauthorized uses of or accesses to the Company&#x2019;s IT Systems, Confidential Data, or Personal Data that would require notification under Privacy Laws (as defined below). </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.31</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Data Privacy Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other processing (collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Processing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (Regulation (EU) No. 2016/679), all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its subsidiaries, and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). To ensure material compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Privacy Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company and its subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, at all times since inception provided </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accurate notice of their Privacy Statements then in effect to its customers, employees, third party vendors and representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.32</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions with Affiliates and Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be described in the SEC Reports that is not so described.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties of Each Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Investor, severally for itself and not jointly with any other Investor, represents and warrants to the Company that the statements contained in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are true and correct as of the date of this Agreement and the Closing Date:</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other Transaction Agreements to which it will be a party and to carry out and perform its obligations hereunder and thereunder.  All corporate, member or partnership action on the part of such Investor or its stockholders, members or partners necessary for the authorization, execution, delivery and performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions contemplated in this Agreement has been taken. The execution, delivery and performance by such Investor of the Transaction Agreements to which such Investor is a party has been duly authorized and each has been duly executed.  Assuming this Agreement constitutes the legal and binding agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against such Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The execution, delivery and performance of the Transaction Agreements by the Investor, the purchase of the Shares in accordance with their terms and the consummation by the Investor of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by such Investor (with or without notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material benefit under (i) any provision of the organizational documents of the Investor, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii) any agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Investor or its respective properties or assets, except, in the case of clause (ii), as would not, individually or in </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the aggregate, be reasonably expected to materially delay or hinder the ability of the Investor to perform its obligations under the Transaction Agreements.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Residency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor&#x2019;s residence (if an individual) or offices in which its investment decision with respect to the Shares was made (if an entity) are located at the address immediately below the Investor&#x2019;s name on the signature pages hereto or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, except as otherwise communicated by the Investor to the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Brokers and Finders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor has not retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement whose fees the Company would be required to pay.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor hereby represents and warrants that, it (i) as of the date of this Agreement is, if an entity, a &#x201c;qualified institutional buyer&#x201d; (as defined in Rule 144A under the Securities Act) or an institutional &#x201c;accredited investor&#x201d; as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act; or (ii) if an individual, is an &#x201c;accredited investor&#x201d; as that term is defined in Rule 501(a) of Regulation D of the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Shares. The Investor further represents and warrants that (x) it is capable of evaluating the merits and risk of such investment, and (y) that it has not been organized for the purpose of acquiring the Shares and is an &#x201c;institutional account&#x201d; as defined by FINRA Rule 4512(c). The Investor understands and agrees that the offering and sale of the Shares has not been registered under the Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor&#x2019;s representations as expressed herein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor is purchasing the Shares solely for the Investor&#x2019;s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however, to the Investor&#x2019;s right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with applicable federal and state securities laws.  Notwithstanding the foregoing, if the Investor is purchasing the Shares as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such account. The Investor has no present arrangement to sell the Shares to or through any person or entity. The Investor understands that the Shares must be held indefinitely unless such Shares are resold pursuant to a registration statement under the Securities Act or an exemption from registration is available. Nothing contained herein shall be deemed a representation or warranty by the Investor to hold the Shares for any period of time.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Experience; Ability to Protect Its Own Interests and Bear Economic Risks</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Shares and has knowledge and experience in finance, securities, taxation, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investments and other business matters as to be capable of evaluating the merits and risks of investments of the kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice as the Investor has considered necessary to make an informed investment decision. The Investor acknowledges that the Investor (i) is a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii) has exercised independent judgment in evaluating its participation in the purchase of the Shares. The Investor acknowledges that the Investor is aware that there are substantial risks incident to the purchase and ownership of the Shares, including those set forth in the Company&#x2019;s filings with the SEC. Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment in the Shares and determined that the Shares are a suitable investment for the Investor. The Investor is, at this time and in the foreseeable future, able to afford the loss of the Investor&#x2019;s entire investment in the Shares and the Investor acknowledges specifically that a possibility of total loss exists.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independent Investment Decision</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor understands that nothing in the Transaction Agreements or any other materials presented by or on behalf of the Company to the Investor in connection with the purchase of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as it, in such Investor&#x2019;s sole discretion, has deemed necessary or appropriate in connection with its purchase of the Shares.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Not Registered; Legends</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering within the meaning of the Securities Act, and the Investor understands that the Shares have not been registered under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the Securities Act, and that the Shares must continue to be held and may not be offered, resold, transferred, pledged or otherwise disposed of by the Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration and in each case in accordance with any applicable securities laws of any state of the United States.  The Investor understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various conditions including, but not limited to, the time and manner of sale, the holding period and on requirements relating to the Company which are outside of the Investor&#x2019;s control and which the Company may not be able to satisfy, and that, if applicable, Rule 144 may afford the basis for sales only in limited amounts. The Investor acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Shares. The Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares or made any findings or determination as to the fairness of this investment.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Investor understands that any certificates or book entry notations evidencing the Shares may bear one or more legends in substantially the following form and substance:</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#x201c;SECURITIES ACT&#x201d;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).&#x201d;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Shares may contain a legend regarding affiliate status of the Investor, if applicable.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No General Solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor acknowledges and agrees that the Investor is purchasing the Shares directly from the Company.   Investor became aware of this offering of the Shares solely by means of direct contact from the Company as a result of a pre-existing, substantive relationship with the Company and/or its advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons, representatives, Affiliates, directors, officers, managers, members, and/or employees, and/or the representatives of such persons. The Shares were offered to Investor solely by direct contact between Investor and the Company and/or its representatives. Investor did not become aware of this offering of the Shares, nor were the Shares offered to Investor, by any other means, and none of the Company and/or its representatives acted as investment advisor, broker or dealer to Investor. The Investor is not purchasing the Shares as a result of any general or public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement, including any of the methods described in Section 502(c) of Regulation D under the Securities Act.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Access to Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Investor acknowledges and agrees that the Investor and the Investor&#x2019;s professional advisor(s), if any, have had the opportunity to ask such questions, receive such answers and obtain such information from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares as the Investor and the Investor&#x2019;s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares and that the Investor has independently made its own analysis and decision to invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by the Investor shall modify, limit or otherwise affect the Investor&#x2019;s right to rely on the Company&#x2019;s representations and warranties contained in this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.13</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Trading Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with the Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that the Investor was first contacted by the Company or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date of this Agreement. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor&#x2019;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor&#x2019;s assets, the representation set forth above shall only apply with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement. Other than to other Persons party to this Agreement and to its advisors and agents who had a need to know such information, the Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes of this Agreement, subject to the terms and conditions of this Agreement and compliance with applicable law, including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto in complying with the terms of this Agreement. The Investor acknowledges that the Company will rely on the acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing, the Investor agrees to promptly notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement are no longer accurate.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Listing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Global Select Market and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the Company&#x2019;s reporting, filing and other obligations under the rules and regulations of Nasdaq.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure of Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day immediately following the date of this Agreement, file with the SEC a Current Report on Form 8-K (including all exhibits thereto, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Document</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) disclosing all material terms of the transactions contemplated hereby and by the other Transaction Agreements and attaching a copy of the form of this Agreement and the other Transaction Agreements as exhibits to such Disclosure Document. Following the filing of the Disclosure Document, no Investor shall be in possession of any material non-public information concerning the Company disclosed to the Investors by the Company or its representatives.  The Company understands and confirms that the Investors will rely on the foregoing representation in effecting securities transactions.  Notwithstanding anything in this Agreement to the contrary, the Company shall not publicly disclose the name of any Investor or any of its Affiliates or advisers, or include the name of any Investor or any of its Affiliates or advisers in any press release or filing with the SEC (other </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than any registration statement contemplated by the Registration Rights Agreement) or any regulatory agency, without the prior written consent of the Investor, except (i) as required by the federal securities laws in connection with (A) any registration statement contemplated by the Registration Rights Agreement and (B) the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii) to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of the Nasdaq Global Select Market.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Integration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale of the Shares to the Investors, or that will be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Removal of Legends</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to Rule 144 or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the Company shall request the Transfer Agent to remove any restrictive legends related to the book entry account holding such shares and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends as soon as reasonably practicable following any such request therefor from the Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection therewith. The Company shall be responsible for the fees of its Transfer Agent and its legal counsel associated with such legend removal.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;" id="swireturnhere"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i) have been registered under the Securities Act pursuant to an effective registration statement; (ii) have been sold pursuant to Rule 144; or (iii) are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information requirements under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance with the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and as soon as reasonably practicable following any request therefor from an Investor accompanied by such customary and reasonably acceptable documentation referred to above, (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry shares, and (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Investor agrees to furnish the Company with any information, representations and forms as shall reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fees and Commissions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall be solely responsible for the payment of any placement agent&#x2019;s fees, financial advisory fees, or broker&#x2019;s commissions (other than for Persons engaged by an Investor) relating to or arising out of the transactions contemplated hereby. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflicting Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material respect with the Company&#x2019;s obligations to the Investors under the Transaction Agreements. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members, managers, employees, investment advisers and agents (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Agreements, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally judicially determined not to have resulted from such Person&#x2019;s fraud or willful misconduct. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent Equity Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  From the date of this Agreement until the earlier of (a) thirty (30) days after the Closing Date and (b) the Business Day immediately following the effective date of the registration statement filed pursuant to the Registration Rights Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lock-up Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Company shall not (A) issue shares of Common Stock or Common Stock Equivalents, (B) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Stock or (C) file with the SEC a registration statement under the Securities Act relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement. Notwithstanding the foregoing, the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not apply to (i) the issuance of the Shares hereunder, (ii) the issuance of Common Stock or Common Stock Equivalents upon the conversion, exercise or vesting of any securities of the Company outstanding on the date of this Agreement or outstanding pursuant to clause (iii) of this sentence, (iii) the issuance of any Common Stock or Common Stock Equivalents pursuant to any Company stock-based compensation plans or in accordance with Nasdaq Stock Market Rule 5635(c)(4), (iv) the filing of a registration statement on Form S-8 under the Securities Act to register the offer and sale of securities pursuant to an inducement plan, equity incentive plan or employee stock purchase plan, or (v) the issuance of shares of Common Stock sold pursuant to the Sales Agreement entered into on December 23, 2022, by and between the Company and Stifel, Nicolas &amp; Company, Incorporated.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions of Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to the Obligation of the Investors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The several obligations of each Investor to consummate the transactions to be consummated at the Closing, and to purchase and pay for the Shares being purchased by it at the Closing pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The representations and warranties of the Company contained herein shall be true and correct in all material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the date of this Agreement and as of the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date, except for those representations and </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall have performed in all material respects the obligations and conditions herein required to be performed or observed by the Company on or prior to the Closing Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Injunction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The purchase of and payment for the Shares by each Investor shall not be prohibited or enjoined by any law or governmental or court order or regulation and no such prohibition shall have been threatened in writing.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Shares, all of which shall be in full force and effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Since the date of this Agreement, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion of Company Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall have delivered to the Investors the opinion of Cooley LLP (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooley</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Investors and addressing such legal matters as the Investors and the Company reasonably agree.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a certificate certifying that the conditions specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 6.1(a) (Representations and Warranties)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1(b) (Performance)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1(c) (No Injunction)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1(d) (Consents)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1(f) (Adverse Changes)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1(k) (Listing Requirements)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1(l) (No Injunction)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement have been fulfilled.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secretary&#x2019;s Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate certifying (i) the Amended and Restated Certificate of Incorporation; (ii) the Amended and Restated Bylaws; and (iii) resolutions of the Company&#x2019;s Board of Directors (or an authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the Shares.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall have executed and delivered the Registration Rights Agreement in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to the Investors.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Listing Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. The Common Stock shall be listed on a National Exchange and shall not have been suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the SEC or the National Exchange have been </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">threatened, as of the Closing Date, in writing by the SEC or the National Exchange; and the Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares and Nasdaq shall have raised no objection to such notice and the transactions contemplated hereby.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Injunction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental entity, shall have been issued, and no action or proceeding shall have been instituted by any governmental entity, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Agreements.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as may be agreed to among the Company and one or more Investors in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the number of Shares being purchased by each Investor at the Closing as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to the Obligation of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligation of the Company to consummate the transactions to be consummated at the Closing, and to issue and sell to each Investor the Shares to be purchased by it at the Closing pursuant to this Agreement, is subject to the satisfaction or waiver in writing of the following conditions precedent:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The representations and warranties of each Investor in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto shall be true and correct on and as of the Closing Date, with the same force and effect as though made on and as of the Closing Date and consummation of the Closing shall constitute a reaffirmation by the Investor of each of the representations, warranties, covenants and agreements of the Investor contained in this Agreement as of the Closing Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed or observed by such Investor on or prior to the Closing Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Injunction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The purchase of and payment for the Shares by each Investor shall not be prohibited or enjoined by any law or governmental or court order or regulation.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Rights Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Investor shall have executed and delivered the Registration Rights Agreement to the Company in the form attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as may be agreed to among the Company and one or more Investors in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the number of Shares being purchased by each Investor at the Closing as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the mutual written consent of the Company and the Investors that agreed to purchase a majority of the Shares prior to the Closing;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By the Company if any of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall have become incapable of fulfillment, and shall not have been waived by the Company;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By an Investor (with respect to itself only) if any of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall have become incapable of fulfillment, and shall not have been waived by such Investor; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By either the Company or an Investor (with respect to itself only) if the Closing has not occurred on or prior to the fifth Business Day following the date of this Agreement;</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided, however, that, in the case of clauses (ii) and (iii) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted in the circumstances giving rise to such party&#x2019;s seeking to terminate its obligation to effect the Closing.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event of termination by the Company or the Investor of its obligations to effect the Closing pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, written notice thereof shall be given to the other Investors by the Company. Nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be deemed to release any party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction Agreements.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Statements or Releases</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, neither the Company nor any Investor shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld).  Notwithstanding the foregoing, and subject to compliance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prevent any party from making any public announcement it considers necessary in order to satisfy its obligations under the law, including applicable securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall allow the Investors reasonable time to comment on such release or announcement in advance of such issuance, and the Company will consider in good faith any Investor comments. The Company shall not include the name of the Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC if so required by the applicable rules of the SEC) without the prior written consent of the Investors, except as otherwise required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company shall allow the Investors, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding anything to the contrary in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Investor review shall not be required for Company disclosures that are substantially consistent with prior Company disclosures.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then the earlier of (x) confirmation of receipt or (y) on the open of business on the recipient&#x2019;s next Business Day, (c) three (3) days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to the Company, addressed as follows:</font></div></div><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vor Biopharma Inc.</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">500 Boylston Street, Suite 1350<br>Boston, Massachusetts 02116</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Adi Osovsky<br>Email: aosovsky@vorbio.com</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy (which shall not constitute notice):</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooley LLP<br>1299 Pennsylvania Avenue NW STE 700<br>Washington, DC 20221</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Madison Jones</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Email: madison.jones@cooley.com</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to any Investor, at its address or e-mail address set forth on the signature pages hereto or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or such address as subsequently modified by written notice given in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent to Electronic Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Investor consents to the delivery of any stockholder notice pursuant to the DGCL, as amended or superseded from time to time, by electronic mail pursuant to Section 232 of the DGCL (or any successor thereto) at the e-mail address set forth below the Investor&#x2019;s name on the signature pages hereto or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its e-mail address, and that failure to do so shall not affect the foregoing.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles of Delaware law may apply.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company and each of the Investors hereby irrevocably and unconditionally:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby, to the general jurisdiction of the any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in the State of New York;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or at such other address of which the other party shall have been notified pursuant thereto;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i) are not available despite the intentions of the parties hereto;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own out-of-pocket fees and expenses, including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed investment in the Shares and the consummation of the transactions contemplated thereby; provided, however, that the Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of any Shares to the Investors.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  None of the parties may assign its rights or obligations under this Agreement or designate another person (i) to perform all or part of its obligations under this Agreement or (ii) to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of (x) the Company, in the case of an Investor, and (y) the Investors, in the case of the Company, provided that an Investor may, without the prior consent of the Company, assign its rights to purchase the Shares hereunder to any of its Affiliates or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of such Investor (provided each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ).  In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant to this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Investor covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided to such Investor are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction), other than to such Investor&#x2019;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall promptly provide such information as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor confidential, except (i) as required by the federal securities laws, rules or regulations and (ii) to the extent such disclosure is required by </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other laws, rules or regulations, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq. The Investor acknowledges that the Company may file a copy of this Agreement and the Registration Rights Agreement with the SEC as exhibit to a periodic report or a registration statement of the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Reserved]</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby. Notwithstanding the foregoing, the Indemnified Persons are intended third-party beneficiaries of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independent Nature of Investors&#x2019; Obligations and Right.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The obligations of each Investor under this Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance obligations of any other Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such obligations or the transactions contemplated by this Agreement. The Company acknowledges and each Investor confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Investor also acknowledges that Cooley has not rendered legal advice to such Investor. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company has elected to provide all Investors with the same terms and Transaction Agreements for the convenience of the Company and not because it was required or requested to do so by any Investor.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.13</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.14</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.15</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement; Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto), together with any side letter agreements with any of the Investors, constitute the entire agreement between the parties hereto respecting the subject matter of this Agreement and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter of this Agreement, whether written or oral.  No amendment, modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed by the Company and the Investors of at least a majority in interest of the Shares then held by the Investors, provided that prior to the Closing the consent of all Investors shall be required. Notwithstanding the foregoing, this Agreement may not be amended and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to all Investors in the same fashion.  The Company, on the one hand, and each Investor, on the other hand, may by an instrument signed in writing by such parties waive the performance, compliance or satisfaction by such Investor or the Company, respectively, with any term or provision of this Agreement or any condition hereto to be performed, complied with or satisfied by such Investor or the Company, respectively.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.16</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the Closing and the delivery of the Shares in accordance with their respective terms. Each Investor shall be responsible only for its own representations, warranties, agreements and covenants hereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.17</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Interpretation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This Agreement is the joint product of each Investor and the Company and each provision of this Agreement has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.18</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arm&#x2019;s Length Negotiations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of the Shares were determined as a result of arm&#x2019;s-length negotiations. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.19</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver of Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each party to this instrument acknowledges that Cooley has acted as counsel solely to the Company with respect to this instrument and the transactions contemplated hereby (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and has negotiated the terms of the Financing solely on behalf of the Company.  Cooley may have, in the past, represented and/or may, now or in the future, represent the Investor and/or its affiliates in other matters, including matters that are similar, but not substantially related, to the Financing. The applicable rules of professional conduct require that Cooley inform its clients of these representations and obtain their waivers of the conflicts that may arise from such representations. Each of the Company and the Investor hereby (i) acknowledges that such party has been advised about such circumstances and has had an opportunity to ask for additional information; (ii) acknowledges that, with respect to the Financing, Cooley has represented solely the Company and no other party; and (iii) gives its informed consent to Cooley&#x2019;s representation of the Company in the Financing and Cooley&#x2019;s representation of the Investor and/or its affiliates in other matters. </font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Remainder of Page Intentionally Left Blank.]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the parties hereto have executed this Agreement as of the day and year first above written.</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPANY:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br><br>Vor Biopharma Inc.</font></p><p style="margin-left:40%;text-indent:-7.452%;padding-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:<br>Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the parties hereto have executed this Agreement as of the day and year first above written.</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTOR:</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[NAME]</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address:<br>[&#x25cf;]<br>Email: [&#x25cf;]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTORS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:55.9%;box-sizing:content-box;"></td>
     <td style="width:2.94%;box-sizing:content-box;"></td>
     <td style="width:15.7%;box-sizing:content-box;"></td>
     <td style="width:2.94%;box-sizing:content-box;"></td>
     <td style="width:22.52%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investor Name</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Purchase Price</font></p></td>
    </tr>
    <tr style="height:15.1pt;background-color:#deeaf6;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TCG CROSSOVER FUND II, L.P.</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,669,039</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:1.278%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$37,499,997.95</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TCG CROSSOVER FUND III, L.P.</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,669,039</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:1.278%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$37,499,997.95</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TOTAL:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:0.556%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,338,078</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:center;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:1.278%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$74,999,995.90</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> DOCPROPERTY&#34;SWDocID&#34; .</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM OF REGISTRATION RIGHTS AGREEMENT<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>vor-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-27T07:19:04.8589+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REGISTRATION RIGHTS AGREEMENT</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS REGISTRATION RIGHTS AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated as of March 26, 2026, is entered into by and among Vor Biopharma Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the several investors signatory hereto (individually as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively together with their respective permitted assigns, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investors, and the Investors have agreed to purchase, severally and not jointly, an aggregate of 5,338,078 shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to the Purchase Agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and applicable state securities laws.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="lastspot"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledged, the Company and the Investors hereby agree as follows:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DEFINITIONS.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, the following terms shall have the following meanings:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and (ii) any &#x201c;free writing prospectus&#x201d; as defined in Rule 405 under the Securities Act, relating to the terms of the offering of any portion of the Registrable Securities.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registered</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; refer to a registration effected by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and providing for offering securities on a continuous basis, and the declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrable Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Shares and any Common Stock issued or issuable with respect to the Shares as a result of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be Registrable Securities upon the date on which the Investors shall have resold all the Registrable Securities covered by the Registration Statement. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all registration and filing fee expenses incurred by the Company in effecting any registration pursuant to this Agreement, including (i) all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated with filings required to be made with the SEC, FINRA or any other regulatory authority, (ii) all fees and expenses in connection with compliance with or clearing the Registrable Securities for sale under any securities or &#x201c;Blue Sky&#x201d; laws, (iii) all printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv) all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of any special audit and cold comfort letters required by or incident to such performance). </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act, that Registers Registrable Securities, including the related Prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws. &#x201c;Registration Statement&#x201d; shall also include a New Registration Statement (as defined below), as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus subsequently filed with the SEC.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all similar fees and commissions relating to the Investors&#x2019; disposition of the Registrable Securities.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REGISTRATION.</font></div></div><p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Registration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall, as promptly as reasonably practicable and in any event no later than thirty (30) days after the Closing Date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), prepare and file with the SEC an initial Registration Statement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) covering the resale of all Registrable Securities. Before filing the Registration Statement, the Company shall furnish to the Investors a copy of the Registration Statement. The Investors and their counsel shall have at least three Business Days prior to the anticipated filing date of a Registration Statement to review and comment upon such Registration Statement and any amendment or supplement to such Registration Statement and any related Prospectus, prior to its filing with the SEC. Subject to any SEC comments, such Registration Statement shall include the plan of distribution substantially in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall (a) use commercially reasonable efforts to address in each such document prior to being so filed with the SEC such comments as the Investor or its counsel reasonably proposed by the Investor, and (b) not file any Registration Statement or Prospectus or any amendment or supplement thereto containing information regarding the Investor to which Investor reasonably objects, unless such information is required to comply with any applicable law or regulation. The Investors shall furnish all information reasonably requested by the Company and as shall be reasonably required in connection with any registration referred to in this Agreement.  </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effectiveness.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company shall use its reasonable best efforts to have the Initial Registration Statement and any amendment declared effective by the SEC at the earliest possible date but no later than the 60th calendar day following the Closing Date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effectiveness Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); p</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rovided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the SEC is closed for operations due to a government shutdown or lapse in appropriations, the deadline shall be extended by the same amount of days that the SEC remains closed for operations. The Company shall notify the Investor by e-mail as promptly as practicable, and in any event, within 24 hours, after the Registration Statement is declared effective or is supplemented and shall provide the Investor with copies of any Prospectus to be used in connection with the sale or other disposition of the securities covered </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thereby. The Company shall use reasonable best efforts to keep the Initial Registration Statement continuously effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the Investors of all of the Registrable Securities covered thereby at all times until the earliest to occur of the following events: (i) the date on which the Investors shall have resold all the Registrable Securities covered thereby; and (ii) the date on which the Registrable Securities may be resold by the Investors without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any other rule of similar effect (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Initial Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sufficient Number of Shares Registered</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event the number of shares available under the Initial Registration Statement at any time is insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration Statement or file a new registration statement (together with any prospectuses or prospectus supplements thereunder, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), so as to cover all of such Registrable Securities as soon as reasonably practicable, but in any event not later than ten Business Days after the necessity therefor arises (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Registration Filing Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company shall use its reasonable best efforts to have such amendment and/or New Registration Statement become effective as soon as reasonably practicable following the filing thereof but no later than the earlier of (a) the 75th calendar day following the initial filing date of the New Registration Statement if the SEC notifies the Company that it will &#x201c;review&#x201d; the New Registration Statement and (b) the fifth  Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the New Registration Statement will not be &#x201c;reviewed&#x201d; or will not be subject to further review (the earlier of such dates, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Registration Effectiveness Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall apply to the New Registration Statement, except as modified hereby.    </font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidated Damages</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If (i) the Initial Registration Statement has not been filed by the Filing Deadline, (ii) the Initial Registration Statement has not been declared effective by the Effectiveness Deadline, (iii) the New Registration Statement has not been filed by the New Registration Filing Deadline, (iv) the New Registration Statement has not been declared effective by the New Registration Effectiveness Deadline or (v) after any Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to such Registration Statement for any reason (including without limitation by reason of a stop order, or the Company&#x2019;s failure to update such Registration Statement), but excluding any Allowed Delay (as defined below) or, if the Registration Statement is on Form S-1, for a period of 20 days following the date on which the Company files a post-effective amendment to incorporate the Company&#x2019;s Annual Report on Form 10-K (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintenance Failure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then the Company will make pro rata payments to each Investor then holding Registrable Securities, as liquidated damages and not as a penalty, in an amount equal to 1.0% of the aggregate amount paid pursuant to the Purchase Agreement by such Investor for such Registrable Securities then held by such Investor for each 30-day period or pro rata for any portion thereof during which the failure continues (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blackout Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Such payments shall constitute the Investors&#x2019; exclusive monetary remedy for such events, but shall not affect the right of the Investors to seek injunctive relief. The amounts payable as liquidated damages pursuant to this paragraph shall be paid in cash no later than five Business Days after each such 30-day period following the commencement of the Blackout Period until the termination of the Blackout Period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blackout Period Payment Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Interest shall accrue at the rate of 1.0% per month on any such liquidated damages payments that shall not be paid by the Blackout Period Payment Date until such amount is paid in full. Notwithstanding the above, in no event shall the aggregate amount of liquidated damages (or interest thereon) paid under this Agreement to any Investor exceed, in the aggregate, 5.0% of the aggregate purchase </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price of the Shares purchased by such Investor under the Purchase Agreement.  Notwithstanding anything in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the contrary, during any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities because any Investor fails to furnish information required to be provided pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within three  Business Days of the Company&#x2019;s request, any liquidated damages that would otherwise accrue as to such Investor only shall be tolled until such information is delivered to the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allowable Delays.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> On no more than two occasions and for not more than 30 consecutive days or for a total of not more than 60 days in any 12 month period, the Company may delay the effectiveness of the Initial Registration Statement or any other Registration Statement, or suspend the use of any Prospectus, in the event that the Company determines in good faith that such delay or suspension is necessary to (A) delay the disclosure of material non-public information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances under which they were made, not misleading (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Allowed Delay</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); provided, that the Company shall promptly (a) notify each Investor in writing of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any material non-public information giving rise to an Allowed Delay, (b) advise the Investors in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 415; Cutback</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in any Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act (provided, however, the Company shall be obligated to use reasonable best efforts to advocate with the SEC for the registration of all of the Registrable Securities) or requires any Investor to be named as an &#x201c;underwriter,&#x201d; the Company shall (i) promptly notify each holder of Registrable Securities thereof and (ii) make commercially reasonable efforts to persuade the SEC that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering &#x201c;by or on behalf of the issuer&#x201d; as defined in Rule 415 and that none of the Investors is an &#x201c;underwriter.&#x201d; The Investors shall have the right to select one legal counsel, at such Investors&#x2019; expense, to review and oversee any registration or matters pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including participation in any meetings or discussions with the SEC regarding the SEC&#x2019;s position and to comment on any written submission made to the SEC with respect thereto. No such written submission with respect to this matter shall be made to the SEC to which any Investor&#x2019;s counsel reasonably objects. In the event that, despite the Company&#x2019;s reasonable best efforts and compliance with the terms of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the SEC refuses to alter its position, the Company shall (i) remove from such Registration Statement such portion of the Registrable Securities (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cut Back Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the Company&#x2019;s compliance with the requirements of Rule 415 (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); provided, however, that the Company shall not name any Investor as an &#x201c;underwriter&#x201d; in such Registration Statement without the prior written consent of such Investor (provided that, in the event an Investor withholds such consent, the Company shall have no obligation hereunder to include any Registrable Securities of such Investor in any Registration Statement covering the resale thereof until such time as the SEC no longer requires such Investor to be named as an &#x201c;underwriter&#x201d; in such Registration Statement or such Investor otherwise consents in writing to being so named). Any cut-back imposed on the Investors pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be allocated among the Investors on a pro rata basis and shall be applied first to any of the Registrable Securities of such Investor as such Investor shall designate, unless the SEC Restrictions otherwise require or provide or the Investors otherwise agree. No liquidated damages shall </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accrue as to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions applicable to such Cut Back Shares (such date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restriction Termination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section 2 (including the Company&#x2019;s obligations with respect to the filing of a Registration Statement and its obligations to use reasonable best efforts to have such Registration Statement declared effective within the time periods set forth herein and the liquidated damages provisions relating thereto) shall again be applicable to such Cut Back Shares; provided, however, that the date by which the Company is required to file the Registration Statement with respect to such Cut Back Shares shall be the tenth day following the Restriction Termination Date and the date by which the Company is required to have the Registration Statement effective with respect to such Cut Back Shares shall be the 55</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day immediately after the Restriction Termination Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RELATED COMPANY OBLIGATIONS.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the Registration Statement and whenever any Registrable Securities are to be Registered pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including on the Initial Registration Statement or on any New Registration Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notifications</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will promptly notify the Investors when any subsequent amendment to the Initial Registration Statement or any New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or where a receipt has been issued therefor or any subsequent supplement to a Prospectus has been filed and of any request by the SEC for any amendment or supplement to the Registration Statement, any New Registration Statement or any Prospectus or for additional information.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company will prepare and file with the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement, any New Registration Statement or any Prospectus, as applicable, that, (a) as may be necessary to keep such Registration Statement effective for the Registration Period and to comply with the provisions of the Securities Act and the  Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with respect to the distribution of all of the Registrable Securities covered thereby, or (b) in the reasonable opinion of the Investors and the Company, as may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Investors.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Review</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any Prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copies Available</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its counsel copies of the Initial Registration Statement, any Prospectus thereunder (including all documents incorporated by reference therein), any Prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company to the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment) and such other documents as Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by Investor that are covered by such Registration Statement, in each case as soon as reasonably practicable upon such Investor&#x2019;s request and in such quantities as such Investor may from time to time reasonably request; provided, however, that the Company shall not be required to furnish any document to the Investor to the extent such document is available on EDGAR.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notification of Stop Orders; Material Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Investors promptly (but in no event later than 24 hours) and shall confirm such advice in writing, in each case: (i) of the Company&#x2019;s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a supplement to the Registration Statement or any Prospectus or for any additional information; (ii) of the Company&#x2019;s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any Prospectus or Prospectus supplement, or any New Registration Statement, or of the Company&#x2019;s receipt of any notification of the suspension of qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material fact made in any Registration Statement or any Prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any Prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of any Prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend any Registration Statement or any Prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth in clause (i) to (iii) of the immediately preceding sentence (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suspension Event</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), but rather, shall only be required to disclose that the event has occurred. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any Prospectus or Prospectus supplement, the Company shall use its reasonable best efforts to obtain the withdrawal of such order at the earliest practicable time. The Company shall furnish to the Investors, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New Registration Statement or any Prospectus, or Prospectus supplement as the case may be.  In the event of a Suspension Event set forth in clause (iii) of the first sentence of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements may resume; provided, however, that if the Company has a bona fide business purpose for not making such information public, the Company may suspend the use of all Registration Statements for up to 60 consecutive calendar days; provided, further, that the Company may not suspend the use of all Registration Statements more than twice, or for more than 90 total calendar days, in each case during any twelve-month period.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confirmation of Effectiveness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If reasonably requested by an Investor at any time in respect of any Registration Statement, the Company shall deliver to such Investor a written confirmation from Company&#x2019;s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities.  </font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Listing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall use best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on the Nasdaq Global Select Market.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall otherwise use best efforts to comply with all applicable rules and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least 12 months, beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subsection 3(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Availability Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the 45</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day following the end of the fourth fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the Company&#x2019;s fiscal year, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Availability Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the 90</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day after the end of such fourth fiscal quarter).</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blue-Sky</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall register or qualify or cooperate with the Investor and their counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by the Investor; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (iii) file a general consent to service of process in any such jurisdiction.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to: (i) make and keep adequate current public information available, as those terms are understood and defined in Rule 144, until the earlier of (A) six months after such date as all of the Registrable Securities may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as there are no longer Registrable Securities; and (ii) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; (iii) furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of or electronic access to the Company&#x2019;s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooperation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the Registrable Securities may reasonably request to the extent permitted by such Registration Statement or Rule 144 to effect sales of Registrable Securities ; for the avoidance of doubt, the Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company&#x2019;s Direct Registration System.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OBLIGATIONS OF THE INVESTORS.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in connection with the registration of the Registrable Securities.  If the Company has not received such completed Investor Questionnaire from an Investor within three Business Days of the Company&#x2019;s request, the Company may file the Registration Statement without including such Investor&#x2019;s Registrable Securities.  </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suspension of Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence of an Allowed Delay or a Suspension Event as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Investor will immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor's receipt of a notice from the Company confirming the resolution of such Allowed Delay or Suspension Event and that such dispositions may again be made; provided, for the avoidance of doubt, that the foregoing shall not limit the right of the Investor to sell or otherwise dispose of the Registrable Securities pursuant to Rule 144 or any other exemption from the registration requirements of the Securities Act or to settle a transaction pursuant to a Registration Statement as to which a contract for such sale was entered into prior to such Investor&#x2019;s receipt of the notice from the Company of the existence of the Allowed Delay or Suspension Event. The Company shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of an Investor in accordance with any sale of Registrable Securities pursuant to a Registration Statement with respect to which such Investor has entered into a contract for sale prior to such Investor&#x2019;s receipt of the notice from the Company of the existence of the Allowed Delay or Suspension Event.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXPENSES OF REGISTRATION.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors pro rata on the basis of the number of Registrable Securities so registered.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEMNIFICATION.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investors, each Person, if any, who controls the Investors, the members, the directors, officers, partners, employees, members, managers, agents, representatives and advisors of the Investors and each Person, if any, who controls the Investors within the meaning of the Securities Act or the Exchange Act (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), against any losses, obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs and costs of preparation), reasonable and documented attorneys&#x2019; fees, amounts paid in settlement or reasonable and documented expenses, (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an Indemnified Person is or may be a </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">party thereto (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Damages</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, any preliminary prospectus or final prospectus, or any amendment or supplement thereof, or (ii) any violation or alleged violation by the Company or any of its subsidiaries of the Securities Act, Exchange Act or any other state securities or other &#x201c;blue sky&#x201d; laws of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses (i) and (ii) being, collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company shall reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable out-of-pocket legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement or prospectus and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of any Registration Statement, any prospectus or any such amendment thereof or supplement thereto, if such in each case if the foregoing was timely made available by the Company; (B) with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Initial Registration Statement, any New Registration Statement or any prospectus, the Investors, severally and not jointly, agree to indemnify, hold harmless and defend, the Company, each of its directors, each of its officers who signed</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Initial Registration Statement or signs any New Registration Statement, each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each,  an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with information about an Investor furnished in writing by such Investor to the Company and reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement, any prospectus or any such amendment thereof or supplement thereto. In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification obligation. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by any Investor pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Promptly after receipt by an Indemnified Person or Indemnified Party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, except to the extent that the indemnifying party is prejudiced in its ability to defend such action.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indemnification required by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which person is later determined to not be entitled to such payment shall return such payment (including reimbursement of expenses) to the person making it.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONTRIBUTION.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the fullest extent permitted by law; provided, however, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses paid by such holder in connection with any claim relating to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASSIGNMENT OF REGISTRATION RIGHTS.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding; provided, however, that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#x201c;Company&#x201d; shall be deemed to refer to such Person and the term &#x201c;Registrable Securities&#x201d; shall be deemed to include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding shall not be required for such transaction.</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An Investor may transfer or assign its rights hereunder, in whole or from time to time in part, to one or more Persons in connection with the transfer of not fewer than 500,000 Registrable Securities, with such number to be adjusted for any stock split or reverse stock split, by such Investor to such Person, provided that such Investor complies with all laws applicable thereto, and the provisions of the Purchase Agreement, and provides written notice of assignment to the Company promptly after such assignment is effected, and such Person agrees in writing to be bound by all of the provisions contained herein.</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#222222;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of this Agreement shall be binding upon and inure to the benefit of the Investor and its successors and permitted assigns.</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENTS AND WAIVERS.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a written instrument executed by (i) the Company and (ii) the holders of a majority of the then outstanding Registrable Securities, provided that (1) any party may give a waiver as to itself, (2) any amendment, modification, supplement or waiver that  disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor or each Investor, as applicable, and (3) any amendments to Section 6 or to the definitions of &#x201c;Filing Deadline,&#x201d; &#x201c;Effectiveness Deadline,&#x201d; or &#x201c;Registration Period&#x201d; shall require the written consent of each Investor. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors may be given by Investors holding all of the Registrable Securities to which such waiver or consent relates.</font></p><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MISCELLANEOUS.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the earlier of (x) confirmation of receipt or (y) the opening of business on the recipient&#x2019;s next Business Day, (c) three days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:10pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.8575102053935906%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">i.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to the Company, addressed as follows:</font></div></div><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vor Biopharma Inc.</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">500 Boylston Street, Suite 1350</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts 02116</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Adi Osovsky</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: aosovsky@vorbio.com</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy (which shall not constitute notice):</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooley LLP</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1299 Pennsylvania Avenue NW STE 700</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, DC 20221</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention:  Madison Jones</font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: madison.jones@cooley.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:10pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:center;">ii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to any Investor, at its e-mail address or address set forth on its signature page to the Purchase Agreement, or to such e-mail address or address as subsequently modified by written notice given in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent to Electronic Notice.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DGCL</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), as amended or superseded from time to time, by electronic mail pursuant to Section 232 of the DGCL (or any successor thereto) at the e-mail address set forth below the Investor&#x2019;s name on the signature page, as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its e-mail address, and that failure to do so shall not affect the foregoing.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Purchase Agreement are incorporated by reference herein </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mutatis mutandis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Recourse</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.</font></div></div><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific Performance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Investor shall be entitled to specific </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of the agreements and obligations of the Company hereunder and to such other injunction or other equitable relief as may be granted by a court of competent jurisdiction.</font></div></div><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cumulative Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page Follows]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPANY:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vor Biopharma Inc.</font></p><p style="margin-left:216pt;text-indent:-22.5pt;padding-left:22.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:<br>Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to Registration Rights Agreement]</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="absolute-block-container" style="margin-left:-1in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-1in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-1in;z-index:3;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.4993in;left:0;padding-left:0in;width:6.5in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.3in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 4096&#34; = &#34;2&#34; &#34; DOCPROPERTY &#34;SWDocID&#34;  4885-9433-7646 &#34; &#34;&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div></div><div class="absolute-block-container" style="margin-left:-1in;z-index:1;position:relative;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTOR:</font></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[NAME]</font></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="margin-left:216pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature Page to Registration Rights Agreement]</font><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Error! No document variable supplied.</font><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#34; = &#34;1&#34; &#34;&#34; &#34;&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="toc496215_7"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLAN OF DISTRIBUTION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distributions to members, partners, stockholders or other equityholders of the selling stockholders;</font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an exchange distribution in accordance with the rules of the applicable exchange; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">privately negotiated transactions; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">short sales and settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a combination of any such methods of sale; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.71822399365712%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any other method permitted pursuant to applicable law. </font></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending the list of selling stockholders to include the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#x201c;underwriters&#x201d; within the meaning of Section 2(a)(11) of the Securities Act (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &#x201c;underwriters&#x201d; within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have agreed with the selling stockholders to use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i) the date on which the selling stockholders shall have resold or otherwise disposed of all the shares covered by this prospectus and (ii) the date on which the shares covered by this prospectus no longer constitute &#x201c;Registrable Securities&#x201d; as such term is defined in the Registration Rights Agreement, such that they may be resold by the selling stockholders without registration and without regard to any volume or manner-of-sale limitations and without current public information pursuant to Rule 144 under the Securities Act or any other rule of similar effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Questionnaire</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">QUESTIONNAIRE</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	Name.</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(a)	Full Legal Name of Investor</font></p>
   <table style="margin-left:14.333%;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:</font></p>
   <table style="margin-left:14.333%;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):</font></p>
   <table style="margin-left:14.333%;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.  Address for Notices to Investor:</font></p>
   <table style="margin-left:1%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Telephone:</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">E-Mail: _____________________________________________________________________</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contact Person:</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.  Broker-Dealer Status:</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(a)	Are you a broker-dealer?</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Yes   &#xf0a8; 	No   &#xf0a8;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(b)	If &#x201c;yes&#x201d; to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Yes   &#xf0a8; 	No   &#xf0a8;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Note:	If &#x201c;no&#x201d; to Section 3(b), the Commission&#x2019;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(c)	Are you an affiliate of a broker-dealer?</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Yes   &#xf0a8; 	No   &#xf0a8;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(d)	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Yes   &#xf0a8; 	No   &#xf0a8;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Note:	If &#x201c;no&#x201d; to Section 3(d), the Commission&#x2019;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.  Beneficial Ownership of Securities of the Company Owned by the Investor.</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(a)	Type and Amount of other securities beneficially owned by the Investor:</font></p>
   <table style="margin-left:14.333%;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.  Relationships with the Company:</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	State any exceptions here:</font></p>
   <table style="margin-left:7.667%;border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.  The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Beneficial Owner: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			Name:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			Title:	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED QUESTIONNAIRE TO:  dbrinton@cooley.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>vor-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-27T07:19:04.6855+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><img src="img246614764_0.gif" alt="img246614764_0.gif" style="width:146px;height:53px;"></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Vor Bio Announces $75 Million Private Placement with TCGX</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">BOSTON, Mass., March 27, 2026 (GLOBE NEWSWIRE)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> &#x2013; Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The financing is led by new investor TCGX.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#34;BAFF/APRIL inhibition represents one of the next major waves of innovation in autoimmune disease, and telitacicept is at the forefront of the field. With compelling Phase 3 data across multiple indications and tens of thousands of patients treated in China, we believe telitacicept's clinical profile and robust safety data to date provide a unique opportunity to bring a differentiated, potentially disease-modifying therapy to patients globally,&#x201d; said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. &#x201c;This financing enables us to accelerate our efforts in generalized myasthenia gravis and, importantly, advance primary Sj&ouml;gren&#x2019;s disease as a key next frontier &#x2013; two large, multi-billion-dollar opportunities where significant unmet need remains and where we believe telitacicept can meaningfully change the treatment paradigm. We are well positioned to deliver on our commitment to maximize the impact of telitacicept for patients and drive long-term value for shareholders.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Our investment reflects the conviction we have in the Vor Bio team and the disruptive potential of telitacicept,&#34; said Cariad Chester, Managing Partner at TCGX. &#x201c;With its differentiated efficacy profile, we believe telitacicept has the potential to become a foundational therapy for multiple B-cell mediated diseases. We are excited to support the pivotal development program of telitacicept and help build Vor Bio into a global leader in treating autoimmune diseases.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Vor Bio intends to use the net proceeds from the private placement to advance the clinical development of telitacicept, including the ongoing global Phase 3 clinical trials for myasthenia gravis and primary Sj&ouml;gren's disease, business development, and for working capital and general corporate purposes.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), or any state or other applicable jurisdiction&#x2019;s securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions&#x2019; securities laws. Concurrently with entering into the securities purchase agreement, Vor Bio and the investors entered into a registration rights agreement pursuant to which Vor Bio has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About Vor Bio</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">www.vorbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About TCGX</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in pioneering healthcare companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCGX has investment teams in San Francisco, Palo Alto, and New York City. For more information, please visit: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">www.tcgcrossover.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;can,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;enable,&#x201d; &#x201c;expect,&#x201d; &#x201c;initiate,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;on-track,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;update,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio&#x2019;s statements regarding the private placement, including expected proceeds, expected use of proceeds and expected closing of the private placement; the potential of telitacicept and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">BAFF/APRIL inhibition, Vor Bio&#x2019;s opportunity to bring a differentiated, potentially disease-modifying therapy to patients globally,  telitacicept&#x2019;s potential to meaningfully change the treatment paradigm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">become a foundational therapy for multiple B-cell mediated diseases, our market opportunities, and other statements that are not historical fact.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including market conditions and failure of customary closing conditions. These and other risks are described in greater detail under the caption &#x201c;Risk Factors&#x201d; included in Vor Bio&#x2019;s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. The results of the clinical trial described in this press release is based on information reported by RemeGen; Vor Bio has not independently verified this data.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Media &amp; Investor Contacts:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br>Carl Mauch</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#467886;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">cmauch@vorbio.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img246614764_0.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img246614764_0.gif
M1TE&.#EA# 8O O<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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MV>#@X.;FYNSL[//S\_GY^2'Y! $     +      ,!B\"1PC_ *\('$BP8$$
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MCS4^!WG[Y5]Q@"7>_A(4OBOGOW_^]]____<D9]F]^ZN;UBLA?0/ !%3 !63
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M)@Z+OJF+0DF,82@9_@ALX6@/!L>5IB>?XJF?WL4S>NB/"JIL#0> ^B>BSJ6
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M?YGE'OKYBTYHH@,=_>Q/_Z+;#Y7NFX3JE%:ZTZ.>_ZGK__[U3WKT 7 @PFX
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MOC-  6 P26(@"?1 [U/@/B9!+\)7&+0=0?$>)50Q&S,Q]9%QSO.IE')#@TE
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M1V_3-GE4ZC0U5[4H*[_T5&.54D',24'&32M"6-N35%ND!+'T2O^I=$JM4\"
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I$%6]U5U]JT/]U65]UIN:26C]UG&]J2$TUWF]UU]:(U#<UX4]R@," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vor-20260326.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-27T07:19:05.3427+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://vorbiopharma.com/20260326" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:vor="http://vorbiopharma.com/20260326" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vor-20260326.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 26, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 26,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VOR BIOPHARMA INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001817229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1591163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Boylston Street, Suite 1350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-6580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VOR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vor-20260326.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="vor-20260326.htm">vor-20260326.htm</File>
    <File>vor-20260326.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vor-20260326.htm": {
   "nsprefix": "vor",
   "nsuri": "http://vorbiopharma.com/20260326",
   "dts": {
    "inline": {
     "local": [
      "vor-20260326.htm"
     ]
    },
    "schema": {
     "local": [
      "vor-20260326.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_f6237d00-fd03-4797-806a-1daf158ca887",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vor-20260326.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6237d00-fd03-4797-806a-1daf158ca887",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vor-20260326.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://vorbiopharma.com/20260326/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-26-127609-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-127609-xbrl.zip
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M5XOKIVRR$L2/E!A,23@M5551/#H@*$ 35:C)1S2.JGQ/*>MU Y1P)::+RNZ
MOT9@\OV7L^YJLK^>^":PWD/NVG(?\M%#OED.W>:&D,VI]QND;9"V+DASN\Z]
M<NQ5^^^:!WC]8,^[IP-NI.N&YC=(VR!M@[1UR:UY$5KO>3-#/H*?-'P!U+W>
M6&PGEFW0^4AT?I@.'U-<\Q2U-.MVV^EZ+^!.OD/^P6EB?*5E3'[%:/9&&;P@
M);U!V@9IKQ)I7?]>4G6U>P-WPN6\6,6+I/='@D?DX(J'I=S#/L;=8)YM,G5?
M7?;JVYT@9=/W?WJ[,RK&\?O_!U!+ P04    " !@0'M<F[>_W9X(   .80
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M9LVEKY+L!F]=.5[97%=E.^<R'N9*I-Y5Y -LL5FLH2*#+1 6 !;EM<Y30@R
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MFA8KS$)'>FM4$$-2$-.'*(@H2__/G^H[D$%-6Q6XCP:B,ZX<XI>.E]_2PI>
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ML,7']J_P?H+N4+;@(F&D_<UL%PV?US/"ET,.C' K<6]G-*[MS(53S,1E:&U
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M;&%U^Z-!M3@?VL++@=&O<:AIOGW:O-TU).I+8A0Z+Z_4)9:7HT=B<F2IP*M
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M9+@FL,.X['KKTS8:')9 #WY'A>!S"NQL+;9-@==<T5_-4^7W9C@6EE' GNX
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M#DD"(ME@!.9MJWKTX:)@][_:HK\JA78*_%$V'B/?J@JA,6H#\"N/?1(XT?9
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MEH^.;S#18&L%6\L4!OIK:]VS\?##/\9EMOCG7W[XQWDSF_[S_P%02P,$%
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MM\.C/A:UEQ21?DV*IIOKK$;),C.CX&P;M15D7! \JUBC1HN-V5JCS.C((XE
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MGWAC$4R_IP?@%$&3&+N5SG,8(BY !O5R&>8D(0N+C?L=&5 YAD\[H6W[:9V
MP4&S^]6NDW;8JLF2&T3&CTF6TS;F/3NIDF3DG64EFEL($="5<<$X8T8TW-*<
M8^#GMZH'>+.6X6]0#%3."HOF=).?K?)T=DV9P@EI!8!A!1'YJKY4/]7W#EIU
MU4+IHP'9N_[(WKT!V3L@>P=D[R.<M$4>ASH')[$@2I2VF.4&8M&T_T=>0YF
M1,>BDJFN(5ZGN+Q)<$3]"M!+#PP_R<%J]I7'0\X060%679&5IJQ21;@W%Z*D
MU',VAATKT;<:#]+:ULC!GZS&22.W*N:V'7V.3E@A$Y%4WMZ"P%402%DEY#J=
MZ[EU>I8;@X58QWG<[]L\RF(YYIRI>7DN\;2)NDG2!I_.18O%3$?V.JN2B&'E
MUS&>(>E)&&9HP[R1)DOCB9;@/8K(MOAK)!6R9P$?,FN 0]_%(1WW_/KR/(FX
MHGP!:4/*&/2,SN$CN?/4N9<Q7-=4GQ1(1MZ4"XZI%$!?L[=-<3S0[11$HU2%
MC,X&($?*@ "-[F]>R)2&Q"CN[,IX!YLF+G@6BXPBRJX0'JG>H_=V*%E3B-.%
M4:!X8K%0P%LT3AJ%QCK4H+#&-0,J$AQDXSJ*:881NX"KBS ^0_@I>A/]L$)*
M7J=\8^-XTWIC9$I.L@*CTS @71<""[G54J@$2Q'R4MLC\UONQ,%O^08*YPS+
MI%_2&G^VB%/+J--WE5<2)%%%<AI-9S"C^&93@IH;9$PR5 LZIWOUV+BL$YTA
M=-9,[*VXH4R(3+<*2!^A0N?.!3IDNP>%]KJL5UA=OB.-\UM4\'@;\.IK$>MU
M4JQ]$I<VA8ET1_RF4-"L!LRR@#A8R<G@IO$,&E0O;2V^#POFS$4]Z;%A5T$R
M;QO>$<'>)*'U7=0S-Y5($$W3D47O:F$SC:]PN(@.Y^!L?7R(EPVB*_K>R;Y8
M+XO0=^H_2]SMA!8P(82.4VU5TG)3+/RGFXHGN&YX:Q(\E1T1C;=8P9$QV,6#
M7?S\>EL]B5VL*O>/O+=5.0["SWT2]",/86IV29A&Y8,BYTH#32BC%4 &ADTN
MQ7F1<67[S0P"TB3NQ@JAI <_?1K+0)W"5&&ND,U&[D!NZ!*\,1CPME1U$>6:
M-*&SDGW#J+<9",8K:GS84'$P$!DK9#/H!MH'T M9B +781(U+ QN+/'&B=MD
MWDRRP@HWKLB3E((!2LR7EMVC6Y+ &SEU(#4RU7C3J !;>2/JAHLCNN$K!#C1
M_ ID^=U"'X'4+*H@LG9:8UO1_IPO$M5<:I49'"/ YPKD(?9:@1]&:(CJ.VD8
M4&H^4U/$/1X17B=@+B9J$:C3?:[GS,*]P0;6.XIIF0,L#4J%U\!@Q%V+,=(W
MONPBNC#0#D)R)!B'QH<D8AHDBFO6]Y1[T(8MH:XY?HW &:OP"B&:?*?$2\$-
M,!NPCW4,F.Y:ZJ,/0M9I7 <*CHFXR3]FD8@9B1@;U&;$X!56LJ6/(S]<_E[X
MQ 17M82F79EIJFX)LE"F<E&-9;<@EJLR%(HW=Y,>3 V!\ C>8BTW:&9)XD+N
M(B,TZT_17,.V$#.OT4*C+ F(&Z70 3CS$3P][D)Y=HEGR63>8$A!*UGZ]\.N
MOZ==;W;NA,JQ434FN$$P^:;V;)N^1:V4BSD(+&\"RFDU;SNA[R0*<K4!LCX@
M,+ 4O3=@*LJD=)^6U715D*6XW D;\^!6_TYDS ]+'5NU>8X8K-JD3C)]&58L
MH21@QUV%T5-I%='.*BC\URH,V@Z\Q7ODVHH;(2:3*!*;+->H'A3GY-R:^%YN
M&CN>9!G<K8$EM-M28@VU3=Y.,U<;5O'J]A2W"B6Y$2/M)4C-X\3*K:@3W1LM
MYT+U#: ;MHDXLO32S,(@6!"$TFKX:GE,M;/0&.9J!ZNM"8HRXJW$*3F!UC%#
M7&^&'>&-"^(^]58^R&T71V&?39Y7)X/E9-8C;+IY XU@<^0=PQ2$5;F%KK87
MS[D+@Q0ZQMX>#-V'R+)IRP_^0RYPA#C96LN)@AUZ7<K /KRAR<6?8]\(ZE23
M%QH=NUHS-$Y#4-^H?'>P&N-I2EA:V=1"[71;>%K[3ND8KKX@ M\LK[^0@2R@
M(B3+N07DP",8,+KKC]'='S"Z T9WP.@^PDES,&"H!FJ^D6V[4.5HX/+CH&J1
M\61AE4[5@K#T\_J=T9X*0;-'QG-0/<4<7>'V<VZ]U88>WQIY%-9+>I=6C56/
M2Y'>8[B V(\M_O[NMZ@M7<OV\NWXO)M=(+-1FV)V"7>K$VJCC=LPQI(6:E5#
M/NI;4 ,NWYR.,#1:';=MJ7/7$$\)H%'(ZD)0Z3J,7N(_9'O"UAHN,UNF-SF'
M%A6E;#!%,MEQ?1W:CM!JSY'[X"Q;:L9K'<J(5'!%_KV^,JVGV>!.*7*(^*XF
MW=?J?2>G[=;CUIF!CG&[2W>W-S@X^,K3#&N >(%$JI6B@FUB'?&7H[V7]\C"
MWB>10^L=S\'CC&$%DN4MY4V_,)%#__%O 'S8\_-B].+%RQ]=A^RVAAM-Q18^
MKS@$3UB0[=5MS36-N;99?$(38F]T\')G^]7^SJO=_?V]@^W7[0"1.T-"]D8/
M@0AY)$/JY+?CRY-WWMN/'SX=G_VW]_'-;Z>_'%^>?CR[>'2@5=\.G7Y7&S(D
M#]0#O/Z30Z;<^?B]Q1!<8?Q=ST1*5)HKPL)!KL SAM9Z_6O)^J0X[7R^#BS?
MA-.7N?A59(+-+,$M2')7.+4W8+%JKBUA7U+9M&TNRAES--D=Q2S,CV]M*;;I
M.[,<Y-QHT]CR70Y;Y<!W(/,&9.G3(4N#YX,L/2/FY3#H7;K7Y?LFRJ\ZR-#-
MGZ!>DWPPXP(K15'?V:QNMZ^%6B5@N4Z*ZK14%_C")HR+F&EO O(,Q*)OF !;
M&L-+] -?4F,<QTPP"D4O@+N%(EY8I(($+Y3U,Q-N(5][<;N*"/MQ6B4RM0$%
M7"+ @#ZJK[5YM15%6&>_^%7FAG_#9*IQN^WIZ9%11-HB<!JX?_=V[B#SAX[I
M]U$RIAMZ]2N6U"+PQ0)=$2JMQ:!K37K:O<G\3D;/9MNRV^B"NPLOHI$T06A?
M GVPI"W0W0"=0D?J[;@JJF[>1B'_6QK-68A=9!S7<U3/-+1V>,2/[<]/OH2@
MVJ:">_1-O)W7>_O\8G.VZM<' &F_2I_VN4$_MJ5P(ES>>%S=NK2CWJZ2BK6Q
MM#!6($GM]]4*E8WMI':"+EUNV["DEV%'T:U:.DG3>0S_4<6J=W3N*31F%\]-
MS88;%/R@X(<^==^^L31<[9PJ=_HD_%K<.L3H<I^VQW,T[N['F?1SY@HM?R6B
MD+4V?)$6@81Z.)5ILA.RA!$BMT6K9(YS7=EB1<7(C>,*\D@B%B:(R6)AGBVP
MI*%*J5F94\6E:GLX%I=B&5@"6@(_0 C^QMYFC9&),<Z<^E;\\K872Q06':&[
M*=*1V%HHJAB(&\-)X(62L DYK$*/BQS?*\1P(B2C!I?,W7D9JLT']3$T1;F7
MC?46[$1T$51?T)[K#\6'6"= OIXA=<>*#)>LCXAN*'I0B"DE@$.>GENQ*_GU
M %=I*C3L-ML(*K]9"_&OXW2S<5N7-<BT)5VM%DEE((3*N,KW%"=E5!5.<DO8
M4[)M=KFSG?-BW0KCA+SLAH[/NC47]/'M]$@B9%E5%$2WF6,J8D\$U:.J^IZ.
M@F_=29&',L#SUQ^>?]"*YA[@^0,\?X#GWW_5J724X$TG6JA2ARS4422(<5+Q
M&Y#;&#++T%0+A7$-5MX%-#S=A&CC;%=N5?1UP_(1V_KD,.!6;I3"X?Z:9'D+
M'G=&;80KI.6 7TUB-#91RY8@%4IJHL4E;#@F?K91?O!3;=EPV;(F.%!Y.Z+2
MD[6?DR $5ZU4':QL!,8--7#7*6M$JX.25* JT+B:3:4VV3=W3JX66>J6V34H
M?]D&DU?] Q$CIMFW4Y^',\,[@GB(,OYO<Z[N6D,\%BX"7)J<1&LIEZ@>&*@U
MM.?B#74M5I0H\QJMB9-WOQR?]RL;LPZQV.W!F7Z6SO0SHC2V 38H>B^P\>)'
M%-/%D?=!44B^I4Q5CP$X!DMX"WHN9@13/#M,AT4@00DT,<TG/56>;S/^PE4N
MD3%A!8DC))9E=OSCN)!0&-_+QJB$Z6GH($9Y<,W4RKI#%/_$4D<V567+N[8R
M<QJB4B07M?L[68W+=O=!IU1YL6D5I).^SR4-#=XZ%$Z'>UMG'M($=K/@,QJ(
M::-C,ZLM\!V'VWDB,.":4&"=#(,IZO,4Y1E\"C[*+,LQ5DP '!.&G]!=;AV+
M7P'JP?!^*[#GB!?W3F_L[*MO?>7FOI1LURI.\97$VK!=9O%8TM8V;MK*HEWG
M9-;3[M\*G9;?9A;Q+FE-+I'=[)Q!;&W9N*3#:B04FF9TE(E?&5;[ RXJ(EG-
M)"WTF*9.?>)D1.RO>*@PB]C*#&^M&QLNJAQ9.8X4=V!C^S"BCH)(UT&NM\P,
M]7:JBB3A,CJ]OC36YT18R5MA!=\U<9*M#AHV3X$DTM:.@:9"P6'!@ZTQJ5-"
MPA3GA[6#.G@N+7;Z=<.QG84;2+O5Z7+1(S=3>=N/Z.#T5BQR\N<;-7;O%H+Y
MKZ+WWJS1>]L'A<<KDV1,PWZGB6Q!WM1FRA%)27#=IFU:G R;?=K50GQ6Q_S>
M5'H.8\&C*O5QH>9.OB)W ;4*;Q&]D5"+(>HNGKDGR*Y)7*#8H*.'Q#GD<6^@
MH@+'?#U00!=&IIW@-/3)Q+*:'*,Y 9MMAGXH[PCJ3M.Y)92KRL8'!A:R$#8=
M7#?J8./UOTXU\F#(S+JKCEQ]C.Y7-WY5W4NGT6@;C'*> _ 4\.=VY *GM^TP
M6QFI&E1 $8>!1,^G @]1F"VT_?%5H:VO6E6W@Q%>SE,%^QW/.04UBQ;,PWTC
M)KL65#%PD")@)!K23-N<::27ZZ>[0\99PHWIH+0P6V>VSCW+3^Z#.'-/(>5F
MU2&\#:<S=5" K[60,QVL;XXB^MJ3E(1;,/^R;DPQRA(S'75$L=HHM&_50H98
MBVHNND.%L6MPSJA/_!C&YF%H%T2ZA-!(6]5T!V)CK]%CC&>@V=^GK?-.TG4*
MV1:O%CBE+]SF0R&\-W);4W<A^[5 7K'F:41 \?$XY#L.P>Z1%(>\.#@L\_GK
M;=G]R!E4+79LM64LKP6LYY;="&E=$#]#D/)Y!BF?47^)MQR=TE[WB6W*]4G%
MD'';3.>PDVJSJ-H&<)QJD/U*J[3-BI1-'ULZ -F4KV;RR&9K(0]FZ! E#059
M:E(7M!K.JY*2J&628$&(3^L=58"-Y\;"T!B;TQ H^\VHK&77;RJ: 'N<-[1/
M(-<CQ<"H58"#GK1.<M4LSLF-U0%@[]V>7*8AS9ZST!^01.N%)'HQ((D&)-%#
M(8D&H^Y>C;KI\S'J?H-M Q?URWQKSRG7 W,AQ6UL#[.CYA&MODX(,B4H\/ 8
M\O:SH(B"?WB_)-D8?,\+;HST(<@_BW)=W,FA@.1Y2I[9\Y$\;W6OE+X+'Q,Q
M;!5#5EZ/("&&83:O$E'(GC/3*E%]:71<OKM=H*JUMLO3+3:P=G^-.LOLO-SM
MO*UO2B@G,<(K%D[:5!=4$!I&1]D=I(>$M?INL8;-^L;];7;W5XQ" V0XL.DB
M(JVN&_'$=_S7U34AKF<>98(;/19P32&)@+!MGTR:RVRHU6T/9XY 1!2BQ;AN
M8KVO.T:7,U?Y_X$UH5W%[S60;5?E$:X_9L,MF*\J#35E]U:,PZ&,J.%Z[T#7
MYI0%19R0=]SSF%+$=/U2]FYD3HN;(N^8N\3EL"!0. Y9/X;#73)C\8;5"'$L
MDNR:"IDPMY92ZSH#NM"-9@)5QI--3)GJSJY'@6 8WAA>-B4\AV'/-2$(HD9&
M.%FP J[,@(&60;"(L#>92ZFA\C [.\CQT<JQ89\]WHD'K^B,5,G4 "=D/9CB
M^%#Y@G7,31$'E4I/S7J6GEH+P$+CV/1I#G4/IKD(4D[1[@_,WU_%_.TRO5N=
MVB<9IN- C1<P.8C"RZ58+57%:M$AYE9698@OH5BHOI<*1]O^K)@?D*"L59]U
MP0KE3Y<@/X<#]B '[/7V<,"^YH!9!@$?KNX=O[G:^>]WJF$("#S/@$#\? ("
M;Y)*;%U\7O9)1K2% W+)=HZ.,</?EXQ/SQ;(56,1$)H\<(.@I\4[;+IJ>1->
M[VCO%GP]WH0P]EQ6@LE3XX<7#N?0&.;;*SXO$6UL,LHV$+_HS*+;;_<M99+N
M-)"?HZ@;R O7#CM_A_EAKAQ2$X_>=V905&W5!,R0&Y?>=58E$0W!1'1JV%EU
M6_16>3K7S+4RL+^X9WX55>^ YX=]UC&,()()SOA4I 1&+8,O3JOZ.RUAD>D[
M#RMW[RO'O;=A]3AZJ)=,M3%&V(O(KV3-%17BF*/8$"J#%35847VSHOYX/E84
M!Q#W]_LD0D8>M9\)/"(7Y$(OBL;6@5]N]=(8Y,R$VA!.//5:WH8L0P"Y@F(&
M_L(L"\/13(D#?H9RR^1=[+0+&2<80[>3"PMLH5;6AX&B+2$^Q9SIO,">F5/,
M) L_JV$S)EOG9&PCSDU*8,0Z#8BI X>++9SQ&5S+R\%V^)P8GX,(S!*T)B5J
M3CW$QH+K^?.Y%(**?N UF+F,MAN\AB1_5C%UG>[8W_=E3U-3NT(A'"28+.(O
M,GPN762G[^G-?,,R0P$;/;+FQ32LDS:DS""H-$LSD81+[A2O\,J"L1K#I@QR
MU98&==2;S49W5N0%A_\SO>7;AZLK1#=;*,11D=$621#J#L9J[K$;L* 4(/5&
M*%T>%FU2ULI-C2EN)_:.E'J5%4$$.,BS%,,R"9FXE)K0W@1QH4ASG%8>WZU)
M<Y)=I\6*_DT^K;-!J)J4AEP;35=&044&E5*R,[:YVG@:\#3+EY9LZI.6_"6N
MD"EF@B&:-\4N0=0CW4& F@CB/"M*JDZ&\1VG:44%1OAD!&V\QR3BSO;6_\9[
M_I6C-<FRY8*_<EIKX^VFG5ASCE1;<LVX/G:U*IV^^IS+*ON;Q0^+&UFF"2+&
MJNQ=Y>.UR9C!HAHLJKY95)^?CT7U5@9V[)/6!ZNJ)335$H-2&G:UNFZ"!J3"
MX^X:4C:2%4%0!Q+@(:8.*#C% :4JM3Z)E,VDZT7KT(WF$)3!8%L!JVH*D+Q<
M&0D3)*76)"?2T+@27B+ 78T4"L<:"MTXK>9C-GHZ+#P)WE'M#16]6!K,F5GL
M]E/<P<?F$H"Q5BAOY$]S7MTTY^.BQ6Y8R9&.$09761RIPHXHJ\9E2TFA!#74
M.X$;-(+21E@E@G.ZF"T+M%JP4 0FS]D@Y2Q'5CN[.A W\#M!<)@,MM1E#B*E
MJ?K?49E";2*6L"#S5L4W%#ZL5^'#RZ'P82A\N$/APV#8#OW#^]P_?'^-^X=;
M_<*]C^^]RU]/O-.SOY]<7'X\'QJ(#^[DT$SW/OLNG9JP4Y_<RI%WXD0;V;.4
M*7X*W\T7B4 715_R5_1DX#72(*:.&1*AF,^]H"SA9K*%$<;,UBLG>_*%V*>\
M-WU:H-MA1U;YHLB2U*2EP:RZ;J9$ON>-2TU$!C:C @Z&UA^]<;<]5#?EI QD
MU]U/BL0W:CV,"ZR=3PV>[^ '_SKJ@,&4')3:T"WX[@2*6/."8:@^B4PXZXY2
M\[T"86J47L,('XJ^/[*8N$ETI18GA\Q/5+J6L/$R!]=@R[49^31QGB38_()1
M1,UP[1TCM!]DZSMP;KEQ:I.I+J@1<JZ3\NPW YVELI"ZTF(S16JY#&/$5:,E
M1D=8U8Y7K^"SU/5JJQ)\)B.O1OCO+BUSYS:3%$,JS$[L=KI#,#VRL>.:^RV5
MO; XD6[>GN/7P12I,,?,E^N0PZT,*TLH*%PDIAE-@ :#4OTJC]?F[+7[8Q
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M.*D%.RBD/_^HHNF<MQ,6AN(N%&F0R&NI]1C]J"B+&SM%A,B7)*_%W<;_(C(
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M4^BLYKT7EEMK>E9I?-HC^[U-\4)IXV_U>W$ @]_[('[OH_,Q?8WCN_V CN\
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M]R66J"GR8\T%=L,A_%8N&)WN2^YF++O*)K#Z^!%:F=E2",/W-E9;(_&RZ]0
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MQ" 8)H<QW]VOXLO3%&NVN;90$A>1+D!(%.D0%2)TS(O@*H@3TBOP&:@6-BU
MT5U9*@ZW!<J?9F303>AH%8_HK#+A&&>A9FZH%'D&E2)[0Z7(4"GR4(V^'E/5
M]IY_;F$4C3)3#7RHJS6J\@!-5QN*5F4V""E._ZC2T/4OC)L"BQ>+"=K,JO]E
M'J2R;C*@CB:D%C &)RCF9H?];F^$MC39V-H;O=S>_U&+=":D'/@H!T/UP0W5
M^?,Q5-]6\TKV53Z7!E^?S%2N-]*FJ(;!RT)LK"L*S1MPXKDT78&51=J\ 8@G
M,%^_^X9_CV"G/OSQ_\HZ^?]SH0L(/B'9ZGMNS?-_GW9^AC[*@WMU:_=J_]'=
M*VER3.(O(N(QM1CY]MS)^UHV&FX"?IL7M#^L559^ RZS,^7.77*]EUS#?/U\
M/E('Z^?R/:SCUY^]U8J">KFKYK@_30H>G!GU],S[_?3R[.3BPOO]UY/SDX_O
M_3Z9B2Y, E%T5*D3<0#RG'I\2D;:<T) 6AD66<U3)4M3/QJ0AXS$I-XDSHM2
MDZ4'X^Q*M+>F&ZS%Y_FN3F^IG1?W=OAW]UVR]EZ?_[<?/WPZ/OOOPSX=^I_'
M.?]?GRFEOZ*O)6\R)]2UNSLZ@,\<52<_Z]]FO.\I?+,\]-:*]>Z''[YU6]X[
MJ"F8BT,<U"7FV7IUBCW/NYU]>9]FH75*Z.)[<T$&;_E)O.5[B@"!*;C25OR_
M*W;JUSO=/+)7M/JW=L#Q0I,(:]UK2&HZ2;+KPUD<@1IQ]YZ]S:QMW#L7S!I4
M, :9#>;YUCC)PL\WC&MKQW+_7[3[G+R"]_*$_0=_PEZWWRQ_2@=2"PI.5M22
M$DZ$!&Y.M4&8-CRD?V%9T,;VXHOOP?_;]/*LI ]&VY&8;II@RL'+UP>[+U^\
M:NPPO.W.]FC_]>L]N+D4!L[FV*YMCKH(M$,S:JYJ&P.OD3MW>[17<]3O1\+1
M;^_3&GIYOV$9[_2]]V]_WML_\MY]?/OWX_/3XS>_G? G%[^_R\+3=[]EW .)
MK]K??OV"__4??-4N_Z7O\>G\XZ>3\\O_=N[!WWK[KUX=;+W>W]O;>OEB_X5G
M_9+^WS?;$O<]-QTR^GY.X<Y-YWQM0Y'K"C]IKNX0B!P"D4,@\OL(SGU/[_I0
M@<@7:Q2'/#W[^\G%Y<?SFQO9?[>AVO]S=OSAI!W$\%#S4^\[VK?HX5H%#X>5
M<X*6P]*M8<C^F\+,P]H]Z=H=<R?'=@W;$WOKP4%P3:]R+=(/% B>YMGUX4YK
M6&)(3WP7Z8G>Q.+N&*>\_TS^/;_029YG^;]BWTI5W.U=!7E,E3!%M2"VA6\O
M\[SG03N1WYUZ_'8=0[F/GG1;VZCNF@),^]Q]JIX<4C!^+X[^XT]E%NZ_?K&[
M<_#_7MY#?.!)+.&3+[-X')?>\0,:@%USV-.0RJ??CL^\C^^]=Z<7E^>G;_YV
M>?KQK->H,^^.:[=[PY,?.#UZGYXG-@8128)D-Q9M3.$K.KC"HWB\+"!CUE%X
M%K+Y(T'<@FAPB"J.<N."^)!TX6M1A2$X1UE>;)%2@5V+5/KZB4A(6LB"USF8
M:#0$YG_A2ZD[5L=E8(P+D%F11UJ(4@D4^5=$"HL\(\:7JO F>3;W@K8W9<K0
M:3PIU<OXBA^GF,4++T+[,1Y7;D&O>ED?RWA]OGT)BT"$>?!?GQYE)L5E^$&W
M0?+D$6%.KCKK,.?,M\V*9+OE/\27<!:D^$ZP)3\+)CG-J>\8=GMAGB+-_4==
M8OBN6"F(%TIBK!0F$ZE:77I4JC;4[Q-SJ;1BOB@]<@'QA]0\/$"J<H%\&/AP
M.1S^$K\CZE6<0:3C"9!C,-!?DW8RG7XZ;D._ /.2^O3(7T8"FX3'V$*H]1DX
M]:6F-->C[1?UR""<:L*)]AAV%JGWJI=E^A.J3*3](<I9%A7<8DIN4_@8UU^>
M'OM0E2SE^H7W_.HB]A8^ !?2YFZ9%27<C)3")Q:'2*E%V*AF4LR\PN[H8._E
MC_W95KNCESNO=G?W7K_>>W'P<F>WO<S]SH7M__;G+[O;N[O:'N\]Z86MS(CR
MG.G?"J/R?/>@N0P62_VQ["C6<C:-<](>%[S7??MBV+??Q;Z%EXY3I' ?YQG\
M@()[-DT[L;#8'\2V2<,_ L<05'Y.KF"('/4+V<T>]FPK>=:P:8=-^RV;EL"2
M;$2OW)#7,5.#BOF"0$TH51U3'/YW2G1P(+C)]%'&-NU[N 1_$,"GN4VZR8\/
MT T"KRU>! G>7!K]9,F[S0Z&0S <@@>@V9)"MF""*W?G.YM3[F7X0K$!NQ<C
MLRN*;22HK^#>PW8=MNN];]<@U2$3-_*#Y$FP\?*(".-TZX:\2H0VART6:763
M89<.N_0!A"K'XI*E';FR[=]AVPW;[OZW73$#"Y,"I[*WHRC+Q+1^M+ZE]!3Q
MM2-5LH[.FY;O)DZ/;'461@-I^O4ME<7LQO+C0G8&&W;YL,OO?Y>7LSRKIJS>
ML7J$XL5Y;;-G"]TG@.-C,Q%-\4I;"IOV%NJ>8%ZH7VHSP\X,#3MZV-$/$(BP
M_2A.GA#5L3%C6Y,L*A01*(YY$.AII=J%$..QBE!@ITJ8L465F"0:=D3A"X9=
M/>SJ!W#5,.T]CE/=:8:RWK@K5=)/9GF/R%@9MN"P!>\_6K"4ZI^W'(J\.=:;
M1IA<**J JU3=[E*CUJUXB[S^BQO&_3SR^JU@&@;FH*E$=/F$Y FK',$K&E.$
MB)AL+EPT32=(YCIE4FNX9H[RP?=B^L'2B\0DJ))2=6II]@E A X^73@M KA%
MG()#L<7(%ZGR9M2[V60BFP;4H_RU$;9.@]4]R_A#/O?_Y&8$7@"R*U+ET77/
MB:\ZKV C[N_N;XPW-_8V6YN@U7J;"N^"IQM?XSC$EM7X&+)WX4L4FR1L.ZP(
M"1K#:WN+K!BHG!^C^N,F:-+M%V]G:)3SW)E*'AO4?N/N7!\%*]60#<IMP^1Z
MA.B5^A/;.+8)\%:EPWTF6J\/DB(C7:>QKROT, R !Q7&>5C-L5<K@45UNCP$
M^]ADJAE>[#MJ=N5+46Y]++J=7,PJRK;510MP> ""]N+-3]OZ?@KR[B@:5^4K
MH-(2U>EW;P+<K:3Z.&#=%LOCA]8B*7KW3< -3<,X2*AO:5Q6.OZ'>QAOC]9D
ME:?PF"FBEPB^;>+ETLJJ'PW^C/H'PQ5Z6&AG:K@UV:P@(*NY6'$H*>:#!Y/,
M3G,8&S/'HT(#579=Q0<40MG;U-\P Y%,\/6JU(AU_)4>%)FD21808%[:[HWW
M0_H>=SJI<:*:*!RQLI&=Y]_F+:W%Y'AK#;G_#8LJ6\/JQK TBQ8$&0:"R3E,
M<EASQALA1Q1ESG,AIW>INX>Y:(?5H[ !S.A1*%^FYACP4^6%=W\(3J=$%]GN
M;-VKV* &P. \4-R$"P;(/V#$?B[ S U+?KXU^YN#;.W%FU]2Y[MI+J:8DY-M
MM M5:]&N-,DUM01PXW [NQ(\;%L/*TB0#!.W_1QD8H'X"T+ZT)'#K^.B8.D2
M4[!OY)WHMJD= \7=FU^)@O.,:.Q2/ 9,A47)7G^933E%HY0*2#-"VQ5M#CAM
MYS\$>L!DH62)4.4QX&#X%(*$&>2^WOH]ZT8/$Y?-@TBU\4Z6+%5DDH@>/_)^
M%SQMV*%+ECIQP<-$5L'(E9*K$4M9 ),PG*Q>O/G-)K+";B;4GKT!X922&XWD
MA4A5L5,=Z(PM)2D\52V0Y "C.SO[^]IN;P9O=%,W4KAD0,R%**5:@]G)XX!,
M '@5C'TI62#5E^S1/N&?(P**ZZA2&4;2+8_%%X2TXOMH@>'D^IW[=0UWV,N]
M>//NO8Q-L$$JT?I=T^X!"=VTJ:10I3U#$5%$?99"F;G=FJ3%E%<UAI0PV F/
M[&?S9]$1"71Y\[D(4EGV=2%]B-V-8'-C9V>S/<#I;<0E/ !_0_>&H63FN+1/
M!'?G1F&-K)3(,!))26\/#\L/$+A%5:?P4AAIUF%E,R\2<NA(]<V1=PP3K=6B
M[RI%6"OT@)6-"H<<5I!/MPC H)9UH1)BZTH8.9]ZH/AR1OVR*-"/ZCZJ\'?+
MQ(":I'+2AULM95T4U1B5LZD3U3:JMK:;,FP0./T4.+R&,#A,9LAEB_Q:,*GA
MO_*)@T,F+TV#N5A9K^9+O40[!4TLUSSEW;^HQDD<ZI.H:YJ=)^#IDH4:QK^R
M-KNO9:65:;'/%5QN#AW9HW)89+1*Z5 E02[32'K;@^X&/0W7(TJ9@<K4IYJ'
MJ@^!<=+@46Q%+]!:S1% ZI/Y@?EO#=*KY9(ZD7K2;Y?, $,$K8_'Z11#("2V
M,VHN#BK(0O]H^9<$UXR;P$PJK7"A-HK<L7Y314OM@8=.JG,X/7;?<KAEFBRU
M@\/;B/Q#C!/!44K17V*;@8\!VPTC#X:-^1:\B:\SO#RN]G%(_4MCJ5+R(T$+
MPGF&3T5:>_0_*E@HPC5A&)CU(F51:Y:KL^_-[\(6,Q;!J=H QO,.']!\XU-P
MQOM['H84:&\(\&ZU>+M#"G1(@0XIT(X9_5UP/X$@NHJYH4 7S%5Y=4%:QEOP
M$(:QDF17U5WG8JH^^V"Y/R<*PXU.""4?%JA8,:*OTCHFA$.N#4=PJ%R=32J,
MXURQ[ET5R*1?<'!R,HD3--CJVK%T#&9;85_+0.(\^(P:<Z$?UHSCQZ76YAT1
M_494=--2>"N#QC)Q(K.MC,XLXV*RU$FMK_/75N>#\$C,4U Y9'F[^8]Z,(+7
MR0VO767)E1I@B^<<3 -,F7BAR/$T@C43C+' .N8L-MK$^&OK8_"%XT)'%@8'
MM/<"!*'R$>/8U%;J/J=R.]QB&W0M/Z,#J4*_9IC[3(1%N['%(:LC'KOR@L/^
MZL6;U_;7C;48R'>%[H[(,5&;H&@,BBSE2/L$_7].S6/_G*^JJX.A<>Y7J ([
MCJ:$Z'-948%4IG71&L$?P8:LLJK -CSZH@H^97BK"'+P?3!D<>AMQ)N<^Z;J
M/X=UKCNB2I,$.QH]NC86O8AB+RZ8-L1.>ZV;GX:_$7</Y,8;I)F79*#T<VO"
M=&Q3\4WCHIACK:.<@4S#(RD=>H:1F! WG30/5K)5^_*G)F?#BEI.S7B%5,*]
MA6 -9T?@1%A?!#DM*RK)*_3M&-$0I&!@;F63+5)]23Q'ZA!-N:-^#N^9X]:2
M8;*8LD;\%!LX<&-JBKUOA:E'ZXNL!'@J!KUX=_57>@W^\WKYSWN#_SSXST_'
MB]UV;-:= _O-8S5!:9^O7K2=Z_7N>*#<PI4 >R/W_EK!?V'3I0'HN6$KW!?Y
M>ZWGF#0!^J)&,?K"( D8G&0*'R\5R(C3-(:0U[8-I1/[EI.5D@!L@9@HA3JX
M#G*L]Y-!.K)_[1O$Q 96@:03#]E^J;X /3^.?_W;R04R[I\=GYZ?M$Z+W15W
M:^=@M/?JX,=:!Z:]T=[>WH]'#S.!O>X'N3/Z 3OIM?>*?>J9Z]G9_V$CV/SA
M?07.]V_@028>3ARZ;$HC6',(IICW<\F=?YH%]3O[/&O2I,6QX\-!T.,OML!%
M C_3Z43S8K2M+X?73X)%(0X+L0A0&K#-C0_4UCS6LU+L;7FH+E=7P661UAMT
M]YUMNGEKES'L$U9&\OX_E7GC2:W3;Q7(LXN 'S1-[)81.=X"==^Q=MOV:/LE
M.A!7 H/802)O!M<VO$EJJBT=!N5?+DII%;J-TM1=.XS>G6_8S]NWVL_=._AK
MO8$U7;'O;UW@'WCD!YG;+7/'K3+WW$!;?N7.)AOQA/ PG+J"JP),\FUR+_1-
M#<?AX&=[Y)* FS.11(>#*.^58!A$^;JMV/>W+H,HOU&4AZVB_ R;F,+?;^'*
M/$N\3^!<@[N[(<N)18#Y%R^55RWX6X39V^5D,,WJKR"1%:J49*3L2D&8R$5V
MS9#0JZP4$G^LP!DU9&@](^;$>C8']= O83.HAW5;L>]O7?JG'GH=E]H=>9[L
M-4]8NK.LI/H4D-XJW'('*7P' ?SZ]3,3P'*9OR_YV[:WUT+X#JLUK-:P6C>M
MEL*,X%OU=N7ZM#ZWU>NWRX&*1"QF<,7AL&+KL6(G6Q^".#GT_M]]_,^PZ.NQ
MZ!A/"<)2QE-N.*M-]^2>G(YO4A[KAUY9E]<=G,]56%EP/M]P[=0[KIVZ*(.R
M*@X' /3Z J#W!P#T (#^&@#T4XO*WJ5Q@LT?CG/A+;.JWN/T?[7JFI9>(M_'
M3/TW_-##:JG)=O#JR/OA++/^[&UES[#Q5T!13B>Z^FUIE;J5F6;OVH/SX7M1
M'-$!45262^1NZD*=,&F*2 L&^E+O7PIR4PGC.$@_4Y&;R*]4#-Q"$@]G;CAS
MSW<YS[)2'-JG+LW:#]UXTU>G0E*,\76OCPHL!YY," * ,(&0&\@BQAY/:#'+
M*JPH%5Z,L\X,24A8F-IT9JU%JQ>JS'B 3]\6_Z$-A]1P>U!)\V!(#$+M>UG.
MC8@,"3H'N;CI+( QD=&UR+K"?!Q2="GRQL@1337K0@HN<![C-,B75HN%<56
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MIR&M:J")X^B> O6F<K!I-1]S L?R",GS0V?/S@K8SY4>G-6HZ,8HR_>T1]^
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MN> 7CY@+_OFG<18M__(O/_\T*^?)7_Y_4$L#!!0    ( &! >URZ#_JOJ@X
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M2)29,NQ\:P!_^<9F)7NF*BO%N-)9TMJZ/MT%F <ME-BAO!Z<R:8@LGENW-C
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M\<9R%HH^FMG1[!O'M)K$:5-6@E6N& ]DG(8"SY2!F[ZVYVA8?WEO; WW]7<
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M<BTR,#(V,#,R-BYH=&U02P$"% ,4    " !@0'M<F[>_W9X(   .80  $
M            @ $4'0  =F]R+3(P,C8P,S(V+GAS9%!+ 0(4 Q0    ( &!
M>UQH0;5O.YH  -XJ!0 .              "  > E  !V;W(M97@Q,%\Q+FAT
M;5!+ 0(4 Q0    ( &! >UP4/KK\^V   "-M P .              "  4?
M  !V;W(M97@Q,%\R+FAT;5!+ 0(4 Q0    ( &! >URZ#_JOJ@X  +-+   .
M              "  6XA 0!V;W(M97@Y.5\Q+FAT;5!+!08     !0 % # !
(  !$, $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>vor-20260326_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vor-20260326.xsd" xlink:type="simple"/>
    <context id="C_f6237d00-fd03-4797-806a-1daf158ca887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001817229</identifier>
        </entity>
        <period>
            <startDate>2026-03-26</startDate>
            <endDate>2026-03-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_3ad6a7bb-0a3c-4e82-b7b2-2ed287acc6b0">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_515be33a-e2b8-4032-88e0-b1ff4c15feeb">0001817229</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_935fe464-e413-44d6-b3f4-50d209de3de9">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_eb1bec00-4e21-4852-8651-b72a5d00609a">2026-03-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_dfa82275-f9bc-472a-bcfe-ab77f3179b3d">VOR BIOPHARMA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_a88734ca-b46b-408f-bc7e-290760dee1a7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_735532d5-7eeb-4c3e-8e00-a729b39787e5">001-39979</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_a8ed75b6-86ed-4088-852b-f2fbe70fe347">81-1591163</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_36f5196c-b933-4cd7-bc2f-26dab9df9379">500 Boylston Street, Suite 1350</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_f5446245-d240-4e80-a7ea-4e0d17a0d440">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_f8abad7e-6c07-451d-add9-762ac45ae212">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_caaf3df7-6311-4175-a800-dc8c7d7ebb3d">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_0bf4d266-efb6-4d35-b707-c544d2c1fa2d">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_8681e0ac-196b-4655-b225-4bb20598b485">655-6580</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_5131cabe-ec52-4066-b8db-1ff659abe7a8">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_821435f4-76d8-451e-9d41-4d54b35ec60d">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_ec4dd139-6f68-4422-895b-75a209bfeeeb">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_87592c07-b026-41c0-8da3-1955e9323a53">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_5c910ee7-6a13-4141-bd97-2a2b01a436f3">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_3a3d56a9-25d7-4ec3-bff5-39c79ae2bb85">VOR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_e4221552-11c1-4f6e-b14e-a2d9af0c210c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_6af7632f-3eb6-4321-8eda-ddf5b2affaeb">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_f6237d00-fd03-4797-806a-1daf158ca887"
      id="F_5894deae-bbf3-4dc4-bcd9-d6be9af5d0f4">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
